Podcasts about Genzyme

In this episode, we're joined by Dr. Mora to discuss Pectoralis Major Tendon Tears — a serious but increasingly common injury in muscular males aged 20-40, especially those who bench press or use anabolic steroids. Dr. Mora is a native of Orange County. He graduated from Anaheim High School in Orange County CA, and went on to complete his training at UC Irvine where he earned top of his class honors with his induction into the Alpha Omega Alpha Medical Society honors. From there, he completed his Orthopedic Surgery training at USC, followed by the completion of a Sports Medicine, Cartilage, Shoulder, and Knee Fellowship at Santa Monica Orthopedic and Sports Medical Group.  He is currently practicing Orthopedic Surgery in Orange County, California.  Dr. Mora's practice focuses on sports related trauma, knee ligament and cartilage repair, shoulder rotator cuff and instability, hip arthroscopy and partial knee replacement and ACL reconstruction. He sees athletes of all levels including professional soccer and UFC/MMA. He is team doctor for the Anaheim Bolts pro indoor soccer team and Foothill High School. Some of the procedures he performs include Cartilage transplantation (Genzyme), partial custom knee replacement, OATS, tibial osteotomies, meniscus transplant, knee ligament reconstruction, shoulder reconstruction, elbow arthroscopy, hip arthroscopy, platelet rich plasma and adult stem cell injections. Dr. Mora's family heritage is Peruvian. He speaks fluent Spanish. Goal of episode: To develop a baseline knowledge of pectoralis major tendon tears. In this episode, we cover: Common patient populations & injury mechanisms Detailed pec anatomy breakdown What to look for during H&P (yes, that loss of pec contour!) Imaging essentials—why MRI is your best friend When non-op treatment makes sense (and when it really doesn't) Surgical tips for acute vs. chronic tears + allograft considerations Post-op protocol that gets your patients back to function safely This episode is sponsored by Arthrex: Do you ever find yourself explaining the same orthopedic conditions over and over to your patients? Save time and enhance patient understanding with OrthoPedia Patient. This incredible website offers a comprehensive library of videos on everything from shoulder arthritis to ACL tears, all in patient-friendly language. Each condition is covered in a series of videos that includes an overview, treatment options, a surgical animation, and more. Plus, it's regularly updated to reflect the latest research. Educate, engage, and empower your patients. Visit Patient.OrthoPedia.com today. OrthoPedia Patient—Educate, Engage, Empower.

Synopsis: In this episode of Biotech2050, host Rahul Chaturvedi sits down with Neil F. McFarlane, President and CEO of Zevra Therapeutics, to explore his unique leadership journey from military nurse to biotech executive. Neil shares reflections from his time at Genzyme and UCB, insights on running a rare disease-focused biotech, and the art of mission-driven leadership. He dives into Zevra's recent therapeutic milestones, regulatory strategies, and the importance of reflection in high-stakes environments. This conversation offers powerful takeaways for anyone navigating biotech leadership, board management, or rare disease innovation. Biography: Neil F. McFarlane took the reins as President and CEO of Zevra Therapeutics, a commercial-stage rare disease therapeutics company, in October 2023, bringing with him a wealth of experience in the biopharma industry and specific expertise in neurological and rare diseases. Before joining Zevra, he served on the board of Collegium Pharmaceutical Inc. from 2022 to 2024 and was the CEO of Adamas Pharmaceuticals, Inc., a biopharmaceutical company developing treatments for neurological diseases, from 2019 until its acquisition by Supernus Pharmaceuticals in 2021. Prior to Adamas, Mr. McFarlane was Chief Operating Officer at Retrophin, Inc. (now Travere Therapeutics, Inc.), from 2016 to 2019, where he managed day-to-day operations. He also held roles of increasing responsibility at UCB, Inc., Genzyme Corporation (now Sanofi), and Sangstat Medical Corporation, which was acquired by Genzyme.

Synopsis: Join host Alok Tayi as he welcomes David Meeker, CEO of Rhythm Pharmaceuticals, for an inspiring conversation on the transformative journey of rare disease biotech. David shares his incredible path from practicing physician to biotech visionary, recounting his experiences at Genzyme, where he helped shape the rare disease business model and set the stage for a wave of life-changing innovations. In this episode, David dives deep into the breakthroughs and hurdles of developing therapies for rare diseases, the pivotal role of patient-centric approaches, and how advancements in precision medicine are reshaping treatment for conditions like genetic obesity. He also explores the evolving relationship between biotech and big pharma, the critical impact of regulatory decisions, and the essential elements of building a thriving biotech company today. Don't miss this captivating discussion packed with actionable insights, industry wisdom, and a look at the future of rare disease therapeutics. Biography: Dr. David Meeker, a member of Rhythm's Board of Directors since 2015 and Chairman of the Board since 2017, was appointed President and Chief Executive Officer of the Company in July 2020. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology, and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme's commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker earned his MD from the University of Vermont Medical School and completed the advanced management program at Harvard Business School.

Synopsis: Abe Ceesay, CEO of Rapport Therapeutics, sits down with host Rahul Chaturvedi to reveal how precision neuroscience is driving revolutionary treatments for neurological disorders. They explore Rapport's cutting-edge lead program targeting focal epilepsy and discuss the groundbreaking advancements that are reshaping the landscape of drug development. Abe also shares his dynamic leadership journey, offering insights into the biotech industry's future and how innovative approaches are delivering life-changing treatments. Don't miss this powerful discussion on the future of precision medicine and the hope it brings to patients with neurological conditions. Biography: Abe brings nearly two decades of biopharmaceutical industry experience to Rapport. He served as President of Cerevel Therapeutics from May 2021 through February 2023, and was previously CEO of Tiburio Therapeutics, where he built a fully integrated company that led to the investigational new drug enablement for a rare neuroendocrine tumor. Prior to joining Tiburio, Mr. Ceesay held positions including Chief Operating Officer at scPharmaceuticals, Head of Commercial at Keryx Biopharmaceuticals, Vice President of Marketing at Ironwood Pharmaceuticals, and roles of increasing responsibility at Sanofi, formerly Genzyme. Mr. Ceesay serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston. He earned his bachelor's degree from Ithaca College and Master of Business Administration from Suffolk University's Sawyer School of Management.

For decades, academic clinical trials consortia have collaborated to optimize outcomes for childhood cancers through evaluating incremental improvements in conventional multi modality treatment regimes. There are now increasing opportunities to partner with industry to test new medicines in academic-sponsored trials, but these collaborative studies rarely contribute to marketing authorizations. Under the auspices of the multistakeholder platform ACCELERATE, a working group of representatives was convened from clinical academia, the pharmaceutical industry, the European Medicines Agency, US Food and Drug Administration, and patient advocacy to explore why this is the case and to seek solutions to enable academic-sponsored trials to directly contribute to the licensing of new medicines. This presentation summarizes the group's findings and provides an industry perspective on how to move forward.Dr. Barry is a board-certified pediatrician and pediatric hematologist/oncologist with over 15 years of experience in drug development. Prior to joining Day One in 2021, she was the Global Clinical Lead for Pediatric Oncology at Pfizer, as well as Head of Pfizer's Pediatric Oncology Leadership Team where she oversaw more than 10 pediatric oncology clinical programs. She has also held previous roles at Genzyme and Millenium/Takeda focused on the development of oncology therapeutics in adults. Dr. Barry serves on the Industry Advisory Council for CureSearch and is a member of the ACCELERATE Platform Steering Committee. She is also a co-chair of the Children's Oncology Group Industry Relations Council. Dr. Barry is a graduate of the pediatric hematology/oncology fellowship program at the Dana Farber Cancer Institute and Children's Hospital Boston, and the pediatric residency program at Tufts. She received her M.D. at Yale University School of Medicine and also obtained a Masters in Medical Science degree from Harvard Medical School.

Episode 54 of LRTU wants us to know about Tony Martignetti, the founder and chief inspiration officer at Inspired Purpose! With over 25 years of experience in the life sciences and tech sectors, Tony brings a wealth of knowledge and a unique perspective on leadership. He shares his journey from being a pre-med major to holding pivotal roles in biopharma companies like Genzyme and Sarepta, before transitioning to a career in leadership coaching. Throughout the episode, Tony emphasizes the importance of curiosity, compassionate leadership, and creating environments that foster innovation and connection. His grounded leadership framework, centered on the three C's—connection, curiosity, and compassion—offers valuable insights for leaders at all levels.Tony also discusses his bestselling books, "Climbing the Right Mountain" and "Campfire Lessons for Leaders," where he delves into finding fulfillment in the journey rather than the destination. He highlights the significance of embracing a beginner's mind, encouraging leaders to ask questions and remain open to new ideas. Through meaningful anecdotes and practical advice, Tony illustrates how leaders can unlock their true potential and inspire their teams. Join us for an inspiring conversation that explores the transformative power of curiosity and the impact of compassionate leadership in driving innovation and success.

In this episode of Medsider Radio, we had an insightful discussion with Timothy Boire and Geoffrey Lucks, co-founders of VenoStent. The company is developing SelfWrap, a bioabsorbable wrap to improve the success rate of vascular surgeries, starting with dialysis access creation for chronic kidney disease (CKD) patients.    Tim holds a Ph.D. in Biomedical Engineering from Vanderbilt University. He has experience as a Research Associate at Genzyme and was an Entrepreneurial Lead at NSF I-Corps. Geoffrey is a venture partner at Pioneer Fund and has a BA in Economics, Biology, and Zoology from the University of Wisconsin, a Master's in Bioethics from the University of Pennsylvania, and an MBA in Finance from Vanderbilt University. In this interview, they talk about understanding your end user, working collaboratively with FDA, structuring and executing large clinical trials, and staying resourceful to attract funding while developing your concept.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and a curated investor database to help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VI. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tim Boire and Geoffrey Lucks.

Show Notes: Julie Lin was a medical student at Columbia's College of Physicians and Surgeons when she met her future husband. It was the first day of medical school and they met while attending a class where they were both serious amateur classical musicians. Julie talks about their shared love of music and how they planned to have a family quartet.  The All-state Orchestra Model Julie shares her story of starting an orchestra at medical school, which initially had a traditional weekly rehearsal and concert. However, they found that the show rate was low as exam time approached, leading to the creation of the Allstate orchestra model. This model involved distributing music and parts ahead of time, having a three or four-hour rehearsal, and playing in front of an invited live audience. Experiences at Medical School  Julie initially thought she would be a clinician, but during her nephrology fellowship program, she trains to become a specialist in kidney medicine, she also became interested in clinical research. This realization led her to pursue academic nephrology, which was life-changing for her. After her husband's residency and postdoctoral training in Boston, Julie started working as an instructor at Harvard Medical School and attending physician at Brigham and Women's Hospital. As part of her job offer, she negotiated for funding from the nephrology division to obtain a Master's in Public Health from Harvard, focusing on quantitative analysis rather than policy. Working in Nephrology Research Julie worked as an investigator in the Channing laboratory at Brigham and Women's Harvard, where they had ongoing cohort studies of health professionals for over 10 years. She was one of the many NIH-funded investigators in the Nurses Health Study, a cohort study of  >120,000 US nurses who signed up in 1976. A subset of women in the study had submitted blood and urine samples, which allowed for analyses of  change in estimated kidney function over 11 years between 1989 and 2000.   Kidney Function Decline Research  Julie's research included looking at diet, nutrients, foods, and dietary patterns and how they impacted kidney function and change. Work that gained the most media attention was diet work. Her research found that drinking two or more servings of artificially sweetened drinks, likely soda, was associated with a faster kidney function decline in women over 11 years. This was about three times faster than normal aging alone. The researchers adjusted for factors like diabetes and high blood pressure, which are big risk factors for kidney function loss. Julie also talks about research on the Mediterranean diet vs. Western dietary patterns.  Diet for Kidney Health The conversation turns to the concept of the blue zone, which has been associated with longevity and longevity, but that many people living over 100 years in these areas may have exaggerated their age due to poor record keeping. This leads Julie to remark that a main concern for scientists is how well information is being captured and measured.  Julie shares tips on the best diet for kidney health. Low sugar intake is recommended, as it can lead to weight gain and diabetes. Vegetarian diets are also healthy, and fish is recommended as the main source of animal protein. A Clinical Research Career in Industry Julie talks about the reduction in academic research funding, and why she decided to continue her clinical research career in industry, working on clinical trials and developing new drugs. She has worked with Amgen, Genzyme, a rare disease company, as well as at a gene therapy startup called Dimension Therapeutics, which was acquired by Ultragenyx. Her current role is as global project head at Sanofi. She talks about her role and the importance of assessing efficacy and safety of new therapies. Playing in Community Orchestras and Chamber Music Julie explains that, as an amateur musician, she has found it to be a great outlet for her stress and the intense work she had to do while working and taking care of her children when they were younger. She joined a community orchestra in 2012,  since then she has played in a number of community orchestras, including New Philharmonia, Longwood, and Brookline Symphony. Julie has also played with the Mercury Orchestra, founded and conducted by Channing Yu, Class of 93. Recently, she decided to focus on chamber music, which has been her true love. She has a lot of local musician friends to play with. Julie explains that playing chamber music brings a sense of flow and connection to others, making it a great gift.  Influential Harvard Professors and Courses Julie shares her experiences in Harvard's music 180 class, taught by Leon Kirchner and Lynn Chang, which was an intense experience. She also recalls a class where a modern and atonal piece was played by an advanced violinist, which changed her view of Schoenberg's music. She also mentions Helen Vendler's poetry class. Timestamps: 05:38 Medical school experiences, including a non-linear podcast format and a successful orchestra performance 09:30 Career paths in medicine, including becoming a physician scientist, with insights on negotiation for benefits and research in nephrology  16:31 Diet and kidney function, with findings on artificial sweetened drinks and Mediterranean diet 21:17 Aging, nutrition, and kidney health with a former academic researcher turned pharmaceutical industry professional 28:36 Musical experiences and focus on chamber music 33:01 Music, Harvard, and the importance of flow Links: LinkedIn: https://www.linkedin.com/in/julie-lin-md-mph-fasn-71796b2a/   Featured Non-profit The featured non-profit of this episode is Esperanza Shelter, recommended by Caribou Honig who reports “Hi, I'm Caribou Honig, class of 1992. The featured nonprofit of this episode of The 92 report is Esperanza shelter. The shelter does incredibly important work, enabling people and very importantly, their children, to escape abusive relationships throughout northern New Mexico. Equally important, is that they provide a wide range of services to help those survivors get back on their feet, providing everything from emergency shelter to transitional housing to counseling and life skills. My wife and I have been donating to Esperanza shelter since 2020. You can learn more about their work at Esperanza shelter.org. Esperanza for those of you not in the know is the Spanish word for hope. And now here's Will Bachman with this week's episode. To learn more about their work, visit https://esperanzashelter.org/.

In this highlights episode I reflect on what I learned from David Ford about setting up an organisation for restructures. A key message was "prepare more for sharing bad news than for sharing good news, because it is much harder!" People want to know what are the implications for them and what is going to happen so when you talk, you must know what these details are. David Ford⁠ joined Prothena Biosciences as Chief People Officer in March 2024. Prothena is a clinical stage, biotechnology company focused on neuroscience. Before joining Prothena, David spent six and a half years as the Chief Human Resources Officer of Intercept Pharmaceuticals, a New York based biotech focused on non viral liver diseases, that was sold to the Italian pharmaceutical company, Alfasigma, in late 2023.  Before joining the biotech world, David spent fifteen years with Sanofi, initially as the Head of HR for the UK and Ireland, then moving to the Paris headquarters of Sanofi for six and a half years. He transferred to the United States in 2011, initially as the Head of HR for North America, before moving to lead the HR function for the Genzyme rare disease business that had been acquired by Sanofi.   David started his career in New Zealand in the dairy food industry, working in HR roles in New Zealand, Latin America and Europe. David holds a Masters of Business Administration from INSEAD in Fontainebleau.

Difficult conversations may involve redundancy and restructure. When you have recruited someone into a business as a talent and now you need to tell them that they are no longer needed it can be challenging. With recent high profile errors, how organisations create the appropriate space to have these conversations is an art. In this episode we talk to David Ford about his experience of how businesses can set themselves up well in the most challenging situations. David Ford joined Prothena Biosciences as Chief People Officer in March 2024. Prothena is a clinical stage, biotechnology company focused on neuroscience. Before joining Prothena, David spent six and a half years as the Chief Human Resources Officer of Intercept Pharmaceuticals, a New York based biotech focused on non viral liver diseases, that was sold to the Italian pharmaceutical company, Alfasigma, in late 2023.    Before joining the biotech world, David spent fifteen years with Sanofi, initially as the Head of HR for the UK and Ireland, then moving to the Paris headquarters of Sanofi for six and a half years. He transferred to the United States in 2011, initially as the Head of HR for North America, before moving to lead the HR function for the Genzyme rare disease business that had been acquired by Sanofi.   David started his career in New Zealand in the dairy food industry, working in HR roles in New Zealand, Latin America and Europe.   David holds a Masters of Business Administration from INSEAD in Fontainebleau.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/RGD865. CME/AAPA credit will be available until February 28, 2025.Leveraging TROP2 Expression in NSCLC: Expert Perspectives on the Present Evidence and Future Potential of TROP2-Targeting ADCs in Lung Cancer Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerBenjamin Levy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Guardant Health; Janssen Pharmaceuticals, Inc.; Lilly; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; and Pfizer.Faculty/PlannerCharu Aggarwal, MD, MPH, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; BeiGene; Blueprint Genetics; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo/AstraZeneca; Eisai; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Merck and Co., Inc.; Pfizer; Regeneron Pharmaceuticals Inc./Sanofi; Shionogi Inc.; and Turning Point Therapeutics, Inc.Grant/Research Support from AstraZeneca/MedImmune; Genentech, Inc./F. Hoffmann-La Roche Ltd; Incyte; Macrogenics, Inc; and Merck Sharpe and Dohme LLC.Faculty/PlannerProf. Solange Peters, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; Arcus Biosciences; AstraZeneca; Bayer AG; BeiGene; BerGenBio; Biocartis; BioInvent; Blueprint Medicines; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; Daiichi Sankyo Co., Ltd.; Debiopharm International SA; ecancer; Elsevier; F. Hoffmann-La Roche/Genentech; F-star Therapeutics Inc.; Fishawack Health Group; Foundation Medicine, Inc.; Genzyme; Gilead Sciences Inc.; GlaxoSmithKline: HUTCHMED; Illumina, Inc.; Incyte Corporation; Ipsen Biopharmaceuticals, Inc.; IQVIA Inc.; iTeos Therapeutics; Janssen Global Services, LLC; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Merrimack; Mirati Therapeutics, Ind.; Novartis; Novocure; Pfizer; PharmaMar AG; Promontory Therapeutics; Regeneron Pharmaceuticals Inc.; Sanofi; Seattle Genetics; Takeda Pharmaceutical Company Limited; and Vaccibody. All fees to institution.Grant/Research Support from (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen Inc.; AstraZeneca; Biodesix, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Clovis Oncology; F. Hoffmann-La Roche/Genentech; GlaxoSmithKline; Illumina, Inc.; Lilly; Merck Serono; Merck Sharp and Dohme Corp.; Mirati Therapeutics, Inc.; Novartis; Pfizer; and Phosplatin Therapeutics.Other Financial or Material Support for talks in a company's organized public event from AstraZeneca; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; ecancer; F. Hoffmann-La Roche/Genentech; Illumina, Inc.; Lilly; Merck Sharp and Dohme Corp.; Novartis; Pfizer; Sanofi; and Takeda Pharmaceutical Company Limited. All fees to institution. On the Board of Directors for Galencia SA.Faculty/PlannerJacob Sands, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; Lilly; Medtronic; PharmaMar, and Sanofi.Grant/Research Support from Amgen Inc. and Harpoon Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NCG865. CME/MOC/AAPA/IPCE credit will be available until December 29, 2024.Roadmap to Success With Immunotherapy's Dynamic Evolution in Metastatic, Locally Advanced, and Early-Stage NSCLC: Multidisciplinary Best Practices for Exemplary Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerMatthew A. Gubens, MD, MS, FASCO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AnHeart Therapeutics; AstraZeneca; Atreca, Inc.; Bristol Myers Squibb; Cardinal Health, Inc.; Genentech, Inc./F. Hoffmann-La Roche AG; Genzyme; Gilead Sciences, Inc.; Guardant Health; Invitae Corporation; iTeos Therapeutics; Merus; Sanofi; Summit; and Surface.Grant/Research Support from Amgen; Celgene Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OncoMed Pharmaceuticals, Inc.; and Trizell. Research funding to institution.Faculty/PlannerJessica Donington, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Amgen; AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Genentech, Inc./F. Hoffmann-La Roche Ltd.; and Merck & Co., Inc.Faculty/PlannerElaine Shum, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Blueprint Medicines Corporation; Boehringer Ingelheim International GmbH; Genentech, Inc.; Gilead Sciences, Inc.; and Regeneron Pharmaceuticals Inc.Grant/Research Support from DELFI Diagnostics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

The HOPE Study – Approaching Dementia Treatment Differently Lori La Bey talks with Ralph Kern, M.D., who is Chief Medical Officer at Cognito Therapeutics, a company developing a disease-modifying at-home therapy for Alzheimer's Disease. He has over 17 years of biotech experience including senior medical roles at Genzyme, Novartis, and Biogen. Learn: About brain changes Lifestyle factors and genetics If early diagnosis helps At home treatment Light, sound, sensory stimulation Biophysical changes Decreased clinic visits HOPE Study    Watch the Video Interview Below https://youtu.be/dRY6PWEvZds   Listen and Subscribe to Alzheimer's Speaks on Apple Podcast https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432   Listen and Subscribe to Alzheimer's Speaks on Spotify https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3   Contact Cognito Therapeutics Inc.  LinkedIn for Cognito Therapeutics - https://www.linkedin.com/company/cognito-therapeutics-inc./ Twitter for Cognito Therapeutics - @cognitotx LinkedIn for Ralph Kern - https://www.linkedin.com/in/ralphkernsvpbiotech/ Cognito website - www.cognitotx.com HOPE study website - www.hopestudyforad.com   Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/ Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011. Alzheimer's Speaks is part of the Senior Resource Podcast NetworkSupport this Show: https://alzheimersspeaks.com/donate-now/See omnystudio.com/listener for privacy information.

A Boston Success story, Rhythm Pharmaceuticals brought to market an innovative orphan therapy treating an extremely rare genetic disorder which causes hyperphagia, a pathological hunger that leads to abnormal food-seeking behaviors, and severe obesity. In this Vital Health Podcast, we have a conversation with Dr. Meeker, the Chairman, President & CEO of Rhythm Pharmaceuticals, who was also formerly the President and CEO of Genzyme. David is one of the world's leading experts in the successful development of therapies for ultra-rare diseases.   David gives his vital insights on the risks posed by the Inflation Reduction Act on the development of orphan therapies, as well as the many uncertainties it creates for biopharmaceuticals investors. We also discuss the problems caused by CMS' continued encroachment into roles normally managed by the FDA, and the implications of Medicare being run like a European-style HTA in the future. As well, we highlight the growing innovative capacity of China in developing next generation therapies, and how this contrasts with the current regulatory pressures being place upon the innovative U.S. biopharma ecosystem.See omnystudio.com/listener for privacy information.

Synopsis: Faraz Ali is the CEO of Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease. Faraz discusses his non-traditional background as an electrical engineer before he found his passion for applying science and technology to healthcare problems. He talks about his experience working at Genzyme and what aspects from his time there he still carries with him today. Faraz also discusses his perspective on the application of genetic modalities, and his team's work pursuing treatment for both rare and prevalent forms of heart disease. Finally, he talks about what it's like being a first time CEO and his thoughts on team building. Biography: Faraz Ali, MBA, is the CEO of Tenaya Therapeutics, a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease. He was most recently Chief Business Officer at REGENXBIO, where he had accountability for corporate development, commercial planning, portfolio strategy, alliance management and corporate communications. Prior to that, Mr. Ali was a Vice President at bluebird bio, where he was responsible for new product planning, program management, patient advocacy and external affairs. He also held roles of increasing global commercial leadership at Genzyme Corporation, where he helped launch multiple first-in-class enzyme replacement therapies for rare diseases. He started his career at General Electric, including technical roles at GE Healthcare and business assignments at GE Corporate. Mr. Ali received his MBA from Harvard Business School and his B.S. from Stanford University. He was appointed to the Board of Directors for The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, in 2022.

Synopsis: Kate Haviland is the CEO of Blueprint Medicines, a global precision therapy company that creates life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, they create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Kate discusses beginning her career at Genzyme before joining Blueprint Medicines, and what the transition to becoming CEO was like after having held various different roles at Blueprint. She also talks about how personalized medicine is transforming patient care, and the company's focus on applying precision medicine to cancer and hematologic diseases. Finally, she dives into how the current environment informs how she approaches leading a publicly traded biotech and her perspective on partnerships. Interested in learning more? Check out their recent approval here: https://rb.gy/4126e Biography: Kate brings an impressive breadth of experience and leadership within the biopharmaceutical industry, as well as a substantial background in business development, commercial and strategic planning, and program management. Since April 2022, Kate has served as Chief Executive Officer of Blueprint Medicines. Kate joined Blueprint in 2016 as Chief Business Officer and later served as Chief Operating Officer, where she served as the founding chair of the portfolio management team, formed and executed business development strategy, drove global capital investment plans, and played a key role in capital market financings. In addition, she worked to drive the transformative growth of the company and support its evolution into a fully integrated business by developing and providing ongoing management of critical functions, including portfolio strategy, corporate development, commercial strategy, international, technical operations, corporate affairs, and information systems. Prior to joining Blueprint Medicines, Kate held leadership roles focused on building emerging, high-growth companies and advancing the development of innovative therapies in oncology and rare diseases as Vice President, Rare Diseases and Oncology Program Leadership at Idera Pharmaceuticals, Head of Commercial Development at Sarepta Therapeutics, Executive Director of Commercial Development at PTC Therapeutics, and roles in both corporate development and project management at Genzyme. She holds a B.A. from Wesleyan University with a double major in Biochemistry/Molecular Biology and Economics and an M.B.A. from Harvard Business School. Kate currently serves as chair of the board of directors at Fulcrum Therapeutics and is a member of the audit and compensation committees.

Harvey Lodish is a Founding Member of the Whitehead Institute for Biomedical Research. He is a Professor of Biology and a Professor of Biological Engineering at the Massachusetts Institute of Technology (MIT). He serves as a Member of the National Academy of Sciences and is an Associate (Foreign) Member of the European Molecular Biology Organization. He is also a Fellow of the American Association for the Advancement of Science, a Fellow of the American Academy of Arts and Sciences, and a Fellow of the American Academy of Microbiology.As a member of the Board of Trustees of Boston Children's Hospital, Professor Lodish chairs the Board of Trustees Research Committee. As the Founding Chair of the Scientific Advisory Board of the Massachusetts Life Sciences Center from 2008 to 2016, he oversaw the state's $1 billion investments in the life sciences.Starting in 1973, his laboratory concentrated on the biogenesis, structure, and function of several important secreted and plasma membrane glycoproteins. To date, his group has made key discoveries in the fields of red blood cell development and therapeutics, long non-coding RNAs, and adipocyte biology. Most recently, his laboratory developed culture systems for generating mature human red blood cells from hematopoietic stem cells.He co-founded Rubius Therapeutics, a company that uses gene- and enzyme-modified red blood cells as vehicles for the long- term introduction of many novel therapeutics, immunomodulatory agents, and diagnostic imaging probes into the human body.Lodish has extensive experience in the biotechnology industry. He was a founding member (1980) and Principal of the consulting company BIA. He was a founder and scientific advisory board member of Genzyme, Inc. He was also a scientific founder of Arris (now Axys) Pharmaceuticals, Inc., and Millennium Pharmaceuticals, Inc. In addition, he was formerly a scientific advisory board member of AstraZeneca, Genset SA, and Dyax Corporation.Alix Ventures, by way of BIOS Community, is providing this content for general information purposes only. Reference to any specific product or entity does not constitute an endorsement nor recommendation by Alix Ventures, BIOS Community, or its affiliates. The views & opinions expressed by guests are their own & their appearance on the program does not imply an endorsement of them nor any entity they represent. Views & opinions expressed by Alix Ventures employees are those of the employees & do not necessarily reflect the view of Alix Ventures, BIOS Community, affiliates, nor its content sponsors.Thank you for listening!BIOS (@BIOS_Community) unites a community of Life Science innovators dedicated to driving patient impact. Alix Ventures (@AlixVentures) is a San Francisco based venture capital firm supporting early stage Life Science startups engineering biology to create radical advances in human health.Music: Danger Storm by Kevin MacLeod (link & license)

In the penultimate episode of Season 4, the GOLD team are joined by Dr Zsuzsanna Devecseri, Vice President and Head of Global Oncology Medical, Sanofi Genzyme, to discuss her career journey and experience within the pharmaceutical industry. Isabel and Zsuzsanna explore a wide range of topics during their conversation, including diversity and inclusion, the importance of climbing the ranks of leadership at the right pace, ensuring personalised medicines can reach patients in need and much more.  If you're interested in learning more about the topic areas discussed in this episode, check out the following content:  Elevating pharma's parental leave policies: https://www.emg-gold.com/post/elevating-pharma-s-parental-leave-policies  Setting the stage for a more equitable future: https://www.emg-gold.com/post/setting-the-stage-for-a-more-equitable-future  Driving access to all medicines: https://www.emg-gold.com/post/driving-access-to-all-medicines  Diversity: from ideas to action: https://www.emg-gold.com/post/diversity-from-ideas-to-action 

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this latest episode, DDW's Megan Thomas is in conversation with Dr Simon Fricker, who just last year was made Chief Development Officer of PepperBio to support the company's next phase of growth and guide the strategic expansion of Pepper's oncology pipeline. Over the course of his career, including eight years as a distinguished scientific fellow at Genzyme/Sanofi, Dr. Fricker worked on three approved drugs: Paraplatin, Fosrenol, and Mozobil. Dr. Fricker was a founder of Canadian biopharma company AnorMED, acquired by Genzyme, and awarded the Queen's Award for Technology for his participation in the development of the anticancer drug Paraplatin.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Mark Bamforth, Entrepreneur, Mentor and Investor in life sciences. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering: How an unsolicited offer led to the unplanned sale of Arranta Bio to global CDMO Recipharm Mark's ability to spot trends of where the sector is going, and sometimes going against conventional wisdom How Mark thinks about investment in early stage and later stage companies, as an investor His take on the tougher, tighter funding environment and what it means for the market Leadership lesson from 20+ years at Genzyme and three founder-to-exit successes Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Mark Bamforth, Entrepreneur, Mentor and Investor in life sciences. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Mark, covering: Mark's backstory from oil barrels to brewing, to a small biotech called... Genzyme A baptism of fire of having to raise money for a self-funded CDMO carve-out after 22 years in the corporate world How a merger strategy led to the sale of Gallus BioPharmaceuticals to Patheon Entering the viral vector space, and the story of Brammer Bio from start-up to a $1.7bn exit to Thermo Mark founded, built, and sold three CDMOs over a period of 12 years. Gallus Biopharmaceuticals was focused on monoclonal antibodies, Brammer Bio produced viral vectors for gene therapy and Arranta Bio produced microbiome, plasmid and mRNA vaccines. In total, over 1,200 jobs were created and over 100 client clinical trial projects were enabled. Prior to this, Mark previously spent 22 years at Genzyme, latterly running the 12-site global manufacturing operation and a pharmaceutical CMO business. He began his career as a petroleum engineer with Britoil, then as a chemical engineer with Whitbread. He serves on the boards of Continuus Pharma, Pneumagen, Enterobiotix, Inceptor Bio, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Synopsis: Josh Mandel-Brehm is the President and CEO of CAMP4 Therapeutics, a company pioneering mRNA amplification by using programmable ASO therapeutics to control gene expression. He joins host Rahul Chaturverdi to discuss the arc of his career and his interest in the intersection of business and science. They dive into the origins of CAMP4 and the inspiration behind the company's name. He also talks about where CAMP4 is from a pipeline development perspective and how he approaches fundraising. Biography: Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics. Mr. Mandel-Brehm previously held roles as an entrepreneur partner with Polaris Partners and key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen's non-malignant hematology franchise and overseeing seminal investments to enter in gene therapy and the ophthalmology field. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company's rare disease business unit. Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan.

Today's guest is James Geraghty, Author, and Writer of "INSIDE THE ORPHAN DRUG REVOLUTION": THE PROMISE OF PATIENT-CENTERED BIOTECHNOLOGY. James discusses why he wrote this book, what orphan drugs are, gave examples of rare diseases, and discussed stories about parents who advocated for their children to have orphan medications to help their children.James Geraghty discussed gene editing, genetic therapies, and why people should get involved with clinical trials!We also discussed the future of treatment for Alzheimer's! In Betsy's opinion, James Geraghty has a heart and a fierce passion for orphan drugs and the families that he has met!James Geraghty has been a Director of eight NASDAQ-Listed biotech companies and chair of Five.James has worked on orphan drugs for over 40 years as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur!

Mark R. Bamforth is an entrepreneur, investor and mentor in life sciences. Mark has founded, built, and sold three contract development and manufacturing organisations (CDMOs) over the last 12 years. His first company, Gallus Biopharmaceuticals, focused on monoclonal antibodies. His second company, Brammer Bio produced viral vectors for gene therapies. His third company. ArrantaBio, produced advanced therapies, including microbiome therapeutics. Previously, Bamforth spent 22 years at Genzyme, latterly running global manufacturing operations. His career began as a petroleum engineer with Britoil, then as a chemical engineer with Whitbread. Bamforth serves on the boards of Continuus Pharma, EnteroBiotix, Inceptor Bio, Pneumagen, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/medicine

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/science-technology-and-society

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/technology

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices

Advances in medicine have made possible better treatments for widespread, familiar human illnesses like cancer, diabetes, and heart disease. Yet there are thousands of much less common diseases, most of genetic origin, each classed as rare because it afflicts only a small number of people. These patient groups were long ignored by a pharmaceutical industry that judged them too small to provide a return on the investment needed to develop an effective remedy. Yet these orphaned diseases collectively caused misery and expense, often far greater than did more common ailments, for tens of millions of individuals and their families. Forty years ago, a revolution that transformed the prospects of patients with rare diseases was lit by three sparks. The passage of the 1983 U.S. Orphan Drug Act resulted from public pressure brought by rare disease patients, their families, and advocates. The AIDS epidemic triggered additional activism, compounded when patients with the rare disease hemophilia became HIV-positive after infusion of tainted blood products. And the third spark was the emergence in the early 1980s of biotechnology companies like Genentech, Amgen, and Biogen employing then-new genetic engineering instead of conventional approaches to pharmaceutical development. Soon after, Genzyme became the first company to develop a treatment for a rare genetic disorder, Gaucher disease, which would come to transform the industry. Jim Geraghty has been a passionate participant in the orphan drug revolution since its inception--a leader in the field as a strategy consultant, biotechnology executive, and venture entrepreneur. Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology (Cold Springs Harbor Lab Press, 2022) is in part a history, with eyewitness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen. And it tells deeply personal stories of patients and parents willing to risk new, untried therapies. But Geraghty also uses his exceptional experience and vantage point to look forward to the immense promise of the newest technologies like gene therapy and gene editing for the treatment of patients today and tomorrow. He concludes with thoughtful consideration of important questions. Why do drugs to treat orphan diseases cost so much? How can we ensure they are affordable? How can their effectiveness be responsibly assessed? And how can access to them be expanded internationally? This book graphically and poignantly illustrates how far an important healthcare revolution has come and reminds us that if not nurtured, it could end before its immense promise has been fulfilled. Learn more about your ad choices. Visit megaphone.fm/adchoices

Jessica Weaver jhttps://jessicaweaver.com/https://www.womenswealthboutique.com/jessica-weaverBOOK: Confessions of a Money Queen: 10 Money Moves to Claim Your Power and ProsperityJames "Jim" Geraghtyhttps://orphandrugrevolution.com/BOOK: author of Inside the Orphan Drug Revolution: The Promise of Patient-Centered BiotechnologyTillamook Jill Allen & Erin McDowellTillamook.comTarget.comJessica Weaver, CFP®, CDFA™, CFS® is a Wealth Advisor, who focuses her work on women. Jess found herself on a mission to help more women gain control, clarity, and confidence over their finances and the next chapter of their life. Through her online presence, public speaking, blog, her book Confessions of a Money Queen, and her Strong Retirement Club, she is able to touch more lives than she ever thought possible and help them elevate their life to the next level. https://jessicaweaver.com/James Geraghty, author of Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology has been a passionate participant in the orphan drug revolution since its inception. James Geraghty has been a director of eight NASDAQ-listed biotech companies and chair of five. He's worked on orphan drugs for over forty years—as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. https://orphandrugrevolution.com/Tillamook Jill Allen & Erin McDowell of Tillamook join the program. For 110 years, Tillamook has stood behind the honest values of farmer-owners. Founded by a collection of farmers, they provide high-quality milk and governing of the Tillamook business. Today, dairy farmers are facing challenges: economic uncertainty, more scrutiny and constant change, to name just a few. While farming is a challenging industry, TCCA is right there with their farmer-owners, providing the support and resources farmers need to not only survive but thrive. https://www.tillamook.com/

This week on The Lebenthal Report we welcome James Geraghty. James Geraghty has been a director of eight NASDAQ-listed biotech companies and chair of five. He's worked on orphan drugs for over forty years—as a strategy consultant, a CEO, a leader of pioneering international operations at Genzyme, and a venture entrepreneur. As a biotechnology executive, he has been a passionate participant in the orphan drug revolution since its inception. His book, Inside the Orphan Drug Revolution: The Promise of Patient-Centered Biotechnology, is in part a history, with eye-witness accounts of advances as they occurred and portraits of the pioneering scientists and physicians, tireless activists, and visionary business leaders who made the revolution happen.

Jake Becraft is co-founder and CEO of Strand Therapeutics, an emerging biotechnology company at the forefront of mRNA therapeutics. With colleagues at MIT's Synthetic Biology Center, he led the development of the world's first synthetic biology programming language for mRNA. Jake has been featured in Fierce Biotech, Bloomberg, and the Boston Business Journal, among others, for his vision and mission at Strand of applying this unique platform for real-world disease applications. Jake was recently named a Termeer Fellow and listed on MIT Technology Review's 35 Innovators Under 35 and Boston Business Journal's 40 Under 40. Outside of science, Jake is an active backcountry snowboarder and trains Brazilian Jiu Jitsu. Lex Rovner is the CEO and cofounder of 64x Bio, a spinout of Harvard Medical School and the Wyss Institute at Harvard University. Using novel high throughput genome engineering and screening technologies in a design loop with computational tools, 64x Bio is developing new ways of generating highly optimized cell lines for the manufacturing of viral vectors. These fundamental advances enable pharmaceutical and biotechnology companies to bring more lifesaving cell and gene therapies to patients by reducing the cost and complexity of manufacturing, a critical bottleneck in this multibillion dollar market. Lex was a postdoc in George Church's lab and cofounded the company along with George, Pam Silver, Jeff Way, and David Thompson. She received her Ph.D in molecular, cellular and developmental biology at Yale University. Josh Mandel-Brehm is President & Chief Executive Officer of CAMP4 Therapeutics and holds a dual appointment as entrepreneur partner with Polaris Partners. Mr. Mandel-Brehm previously held key business development and operations leadership roles at leading biotech companies. Most recently he served as part of the Business Development group at Biogen, where he led multiple strategic activities and corresponding transactions, which included expanding Biogen's non-malignant hematology franchise and overseeing seminal investments to enter the ophthalmology field. Mr. Mandel-Brehm also played an integral role advancing Biogen's gene therapy strategy, executing a series of external collaborations. Prior to Biogen, Mr. Mandel-Brehm held several roles of increasing responsibility at Genzyme as part of the business development group for the company's rare disease business unit. Mr. Mandel-Brehm earned a BA in Biology from Washington University in St. Louis and holds an MBA from the University of Michigan. Nabiha Saklayen is CEO & co-founder of Cellino. Cellino's proprietary technology makes personalized stem cell-derived therapies scalable for the first time. Nabiha was selected as a Pioneer in MIT Tech Review's 35 Innovators under 35 list for her patented inventions in cellular laser editing. She received her Ph.D. in Physics from Harvard University as a Howard Hughes Medical Institute (HHMI) International Fellow. She is also the inaugural Tory Burch Foundation Fellow in Genomics at the Innovative Genomics Institute led by Nobel Laureate Dr. Jennifer Doudna. Nabiha is also a TED speaker and co-creator of I Am A Scientist, an educational program running in 50 states that inspires children to explore science.

In this episode, we cover:Why this mom went from a successful career to becoming a stay-at-home momWorking moms cannot have it all: how society sets us up for failure to juggle careers and our families.Having a flexible career and balanced work-family life should not feel like an unachievable utopia . . . but it does. Delegation is everything: get your family on board so you can truly take care of yourself. Why it's important to have honest conversations with women about what balancing work and family life really looks like.Michelle Sporkin has been a stay-at-home mom for two children, ages 10 and 8, for three years. She spent pent 10+ years working in the medical industry for companies including Johnson and Johnson, Genzyme, Intuitive Surgical and Medtronic. She lives in Manhattan Beach, CA with her family. 

On this episode: Stephanie interviews Dr. Emil Kakkis, MD, PhD and Ryan Dant about the trials and tribulations of bringing a much needed drug to patients in a community desperately hanging on to the hope of one day having treatment and eventually a cure. Dr. Kakkis is a physician and researcher with a relentless work ethic who embarks on one of the greatest challenges presented to the MPS community; finding a treatment for an incurable disease.  An incurable disease that afflicts children and adults, like Ryan Dant.    Saving Ryan was written by Dr. Kakkis to shine a light on the connection between families struggling to save their children and scientists at the beginning of their careers.  The book has many threads and perspectives, guiding readers through the drug development and FDA approval process.   Dr. Kakkis and Ryan Dant discuss their time together during clinical trials for Aldurazyme and the family-like relationship that they've developed.   Ryan speaks about what it was like as a young child in the spotlight and how receiving treatment has altered the course of his life.   Dr. Kakkis not only has an incredible empathy for his patients and the desire to make a difference in their lives, but he is also a leader in the rare disease community.  His experiences with drug development and the manufacturing of Aldurazyme led him to found a pharmaceutical company focused solely on treatment development for rare diseases.  In addition, he is the founder of a non-profit organization dedicated to advocating for legislative changes that will positively impact the lives of all rare disease patients.   To purchase a copy of Saving Ryan, download the latest kindle version from Amazon!  Hardback available soon!Quotes:“What I didn't appreciate was that the science may not be fancy, but is so powerful if it can change the future of the patients in front of you…if you don't help anyone, you haven't really done anything.” --Dr. Emil Kakkis, MD, PhD“When I was younger my parents always told me to not let this disease defeat me, try to live a normal life the best that I can.” --Ryan Dant Mentioned in this episode:AldurazymeThe Ryan Dant Story on 60 MinutesThe Ryan Dant Story in Reader's DigestUltragenyxEveryLife FoundationYou may also be interested in:The Ryan FoundationRaritiesImpositivityThe  National MPS Society exists to cure, support, and advocate for MPS and ML.If you like Our Voices, visit our website and follow us on social media on Facebook, Instagram, Twitter, and LinkedIn. And if you really like the podcast we'd appreciate you telling a friend (maybe even two). 

Stoke Therapeutics & Acadia Pharmaceuticals are working on SYNGAP1 BIG NEWS! https://www.businesswire.com/news/home/20220110005334/en/  FIVE KEY LINKS - Dr. Kaye's presentation - Listen to it again and again https://investor.stoketherapeutics.com/events/event-details/40th-annual-jp-morgan-healthcare-conference - AES 2018 Poster https://www.stoketherapeutics.com/wp-content/uploads/Stoke-Poster-Dec-1.pdf - STOKE Patent https://patents.google.com/patent/WO2017106377A1/en - #OneYearSooner - How we can make clinical trials happen faster https://www.syngapresearchfund.org/post/oneyearsooner - Sign up for Ciitizen - www.Ciitizen.com/SYNGAP1 SPREAD THE WORD Twitter.com/cureSYNGAP1/status/1480546972645793794?s=20 Linkedin.com/feed/update/urn:li:activity:6886314132866506753 Facebook.com/cureSYNGAP1/posts/946801809535615 WHO IS WHO AT STOKE https://www.cshl.edu/research/faculty-staff/adrian-r-krainer/ PhD Harvard 1986 https://www.linkedin.com/in/huwnash/ PhD Harvard 1997, EIR ATP since 2014 https://www.oligotherapeutics.org/officers/isabel-aznarez-ph-d/ PhD Toronto 2006 https://www.linkedin.com/in/barryticho/ MD PhD Chicago https://www.linkedin.com/in/edward-kaye-0a46a710/ MD Loyola Chicago   COMPANIES Stoke https://www.stoketherapeutics.com/ $ACAD Acadia https://www.acadia-pharm.com/ $STOK   OTHER GREAT LINKS DSF on the Monarch https://www.dravetfoundation.org/wp-content/uploads/2020/04/Stoke-Community-FAQ-April-2020.pdf  It starts with Spinraza https://www.ninds.nih.gov/About-NINDS/Impact/NINDS-Contributions-Approved-Therapies/Nusinersen-Spinraza%C2%AE-%E2%80%93-Spinal-Muscular aka https://en.wikipedia.org/wiki/Nusinersen  Grant made in 2003, Phase 1 in 2011 (dec) FDA approval in 2016 (Dec) https://www.curesma.org/fda-approves-spinraza-for-sma/  From: https://www.bizjournals.com/boston/news/2018/01/04/ex-sarepta-ceo-takes-helm-of-genetic-disease.html Kaye said he was recruited by Stoke co-founder Adrian Krainer, with whom he previously worked at Genzyme before joining Sarepta in 2010. Krainer is perhaps best known for being an inventor of another “antisense” drug targeting a genetic disease, Biogen's spinal muscular atrophy treatment Spinraza. “He was one of the real originators of RNA therapy,” Kaye said. “I thought (Stoke) was at a point where it needed to be shepherded from preclinical development into the clinic. It was a really exciting opportunity.” Stoke Origins: https://endpts.com/gene-therapy-startup-stoke-therapeutics-secures-another-90m-in-series-b-funding/ $40M from ATP in 2018. https://www.appletreepartners.com/portfolio#stoke-therapeutics  IPO June 2019 $163M/ https://www.spglobal.com/marketintelligence/en/news-insights/trending/OTV6RnpzTCGYyRs_gx1m7A2  REMEMBER Raise funds at https://syngap.fund/give  Sign up for this 10 minute #podcast #SYNGAP10 here https://syngap.fund/10 if you want a direct link for Apple: https://syngap.fund/10a  Episode 43 of #Syngap10 - January 14, 2022   #StokedAboutStoke #ASO #SYNGAP1 #AcadiaPharma #StokeTx #F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #Genetics

— In March 2016, Codi, the daughter-in-law of Dr. Harold Punnett, one of NervGen's co-founders, fell and became a complete T-11 paraplegic. She has no sensation or function below the level of her belly button and the devastating injury changed the lives of Codi, and the rest of the family. In response to this terrible injury, Dr. Punnett began a personal quest to learn about spinal cord injury. Through his research he discovered a revolutionary nerve regeneration technology of deep biological logic in Dr. Jerry Silver's work at Case Western Reserve University (CWRU). Dr. Silver and Dr. Punnett began a conversation that resulted in the formation of NervGen Pharma Corp. in 2018. Dr. Punnett's hope is that the work performed by NervGen will be able to help Codi and others suffering from paralysis; he is also very excited that the technology may also lead to novel new treatments for other serious neurological conditions such as neurodegenerative diseases.  Valeria Teles interviews Paul Brennan— MSC In Physiology, BSC (Hons) In Life Sciences, President And Chief Executive Officer At NervGen Pharma, And Speaker Paul Brennan is the President and Chief Executive Officer at NervGen Pharma. He has over 30 years of experience in the pharmaceutical and biotech industries working in leadership roles in general management, corporate strategy, commercial planning, business development and regulatory affairs in Canada, Sweden, the United Kingdom, and the United States. Most recently Mr. Brennan's experiences include senior business development and management positions in various biotech companies, including Aquinox Pharmaceuticals, Arbutus Biopharma, Aspreva Pharmaceuticals, and AnorMED Inc. Mr. Brennan has a comprehensive list of business development and licensing transactions, totalling over $3 billion in value: he played key roles in the merger of Tekmira Pharmaceuticals and OnCore BioPharma to create Arbutus Biopharma, in the sale of Aspreva Pharmaceuticals to Vifor Pharma for $915 million and in the sale of AnorMED to Genzyme for $580 million. Prior to working in biotech Mr. Brennan held senior roles in Business Development and Regulatory Affairs at AstraZeneca. Mr. Brennan holds a MSc in Physiology, and a BSc (Hons) in Life Sciences from Queen's University in Kingston, Ontario. To learn more about Paul Brennan and his work, please visit: nervgen.com     — This podcast is a quest for well-being, a quest for a meaningful life through the exploration of fundamental truths, enlightening ideas, insights on physical, mental, and spiritual health. The inspiration is Love. The aspiration is to awaken new ways of thinking that can lead us to a new way of being, being well. 

This is episode 1043 of the Arete Coach Podcast with host Severin Sorensen and his guest Tony Martignetti. In this episode, I speak with Tony Martignetti who is an executive coach, author, and founder of Inspired Purpose Coaching. Tony has an MBA from Northeastern University as well as his PCC (professional certified coach) from the International Coaching Federation. A theme that was consistent throughout this interview was Tony's view of coaching that the "obstacle is the path." Tony started his career journey to executive coaching through his early career as a financial strategist with several large companies including Procter and Gamble, Genzyme, Vertex, and Momenta Pharmaceuticals. He also has experience in running small businesses, including his own financial consulting organization, LifeSci. In 2018, Tony entered the executive coaching industry as the founder and chief inspiration officer of Inspired Purpose Coaching. Through his coaching organization, Tony works “with leaders and their teams to navigate through change and unlock their true potential.” The Arete Coach Podcast seeks to explore the art and science of executive coaching. You can find out more about this podcast at aretecoach.io. This interview was conducted on September 17, 2021 via Zoom Video. Copyright © 2021 by Arete Coach™ LLC. All rights reserved.

Success is the opportunity to elevate what other people are doing. -Catharine Smith This week's story is about a woman who has been leading others since she was in her 20's. From her humble roots in the midwest to traveling to Argentina, Brazil and Uraguay on a Fulbright scholarship, Catharine Smith has always been focused on social action. The time she spent in these countries shaped her views about how economic cooperation can lead to better outcomes for all, especially women and families. The stories women in these countries shared with her are etched in her mind and have followed her on a career path that includes The Harvard Center for Primary Care and the Clinton Foundation, where Catharine was part of a team that worked with faith leaders in the south to create a deeper understanding of our nation's opioid epidemic. These days, you'll find Catharine leading the way as the Executive Director of The Termeer Foundation, one of the most influential foundations in the world. The Termeer Foundation is named after biotech genius, Henri Termeer, the Dutch biotechnology genius and CEO of Genzyme. Created in honor of Henri after his sudden death in 2017 by friends, colleagues and mentees, The Termeer Foundation continues Henri's lifelong work around finding cures for rare diseases, patient centered care and continued mentoring of the next generation of biotech leaders.

Jeffrey Goldberg is the president and CEO of Immunitas. Jeff is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization in multiple therapeutic areas, including oncology, neurology, renal, and other rare and orphan diseases. Prior to joining Immunitas, Jeff was at Akcea Therapeutics, where he was chief operating officer from the time of its formation in January 2015. Previously, Jeff was vice president of business operations, leading both program management and business development at Proteostasis Therapeutics, Inc., a biotech company focusing on neurology and rare diseases. He also spent more than 11 years in positions of increasing responsibility with Genzyme and Sanofi, providing brand management for two marketed products within Sanofi Oncology. Prior to joining Sanofi Oncology, Jeff served as Global Program Lead for Genzyme's stem cell mobilization agent Mozobil, leading the global launch team and overseeing the program management and marketing functions for the product. He began his career at Genzyme as Director, Program Management overseeing the development and launch of Renvela in patients undergoing dialysis. Jeff has both an MBA and a Master's degree in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.

Dr. Almassian is a Senior Pharmaceutical Executive with diverse experience in leading Biotechnology R&D Operations, Project and Alliance Management in startup and mid-size life science companies with an excellent track record of bringing new products through different phases of Research and Development. Dr. Almassian is currently the president and CEO of CaroGen Corporation, a leader in development of immunotherapy vaccines and also Founder and Chairman of Aria Neurosciences (www.Arianeurosciences.com), an Alzheimer drug development company.Prior to CaroGen and Aria, he served as President and CEO of ExSAR Corp. from 2005 to 2010. Over his tenure at ExSAR, he built a pipeline of small drug molecules for potential treatment of genetic diseases and neurological disorders. Prior to joining ExSAR, Dr. Almassian was the Chief Operating Officer at Panacea Pharmaceuticals, Inc. focused on discovery and development of drugs for treatment of cancer and neurological disorders. Before joining Panacea, he held several senior executive positions at Vion Pharmaceuticals (VION), a spin off from Yale University. As Vice President of Drug Development, he built the drug development operations, which led to the IND filing and development of five drugs and biologics through all phases of development. Before Vion, he was held both scientific and management positions at Genelabs and Genzyme.Dr. Almassian holds a MS and PhD from Northeastern University and Massachusetts College of Pharmacy, respectively and was a NIH postdoctoral fellow at Boston University Medical School.

Rozhovor s Danielem Gladišem, ředitelem Vltava Fund SICAV a autorem knih Naučte se investovat a Akciové investice, o lekcích, které se během své 30 leté kariéry na kapitálových trzích naučil. BIO: Dan vystudoval VUT Brno. V letech 1993-1998 byl ředitelem společnosti Atlantik finanční trhy, a.s., člena Burzy cenných papírů Praha, kterou založil. V letech 1999-2004 byl ředitelem ABN AMRO Asset Management (Czech), a.s. V roce 2004 založil investiční fond Vltava Fund SICAV. Vltava Fund je globální akciový investiční fond určený pro kvalifikované investory. Daniel Gladiš je autorem knih Naučte se investovat a Akciové investice. “Porozumění psychologie trhů a psychologie sobě samému  je  jedna z nejdůležitějších věcí. A ta druhá je umět ocenit společnost.”“Ať vyděláte nebo proděláte, je potřeba být k sobě upřímný a říct si, zda-li jste génius nebo úplný trotl, a nebo jestli je to do jisté míry náhoda a štěstí.” “Bublina nastává tehdy, když lidé na trzích vydělávají disproporčně víc peněz v poměru k jejich inteligenci a pracovní etice.”“Jakmile si člověk najde příliš dobrý vztah k managementu firmy, do které investuje, ztratí soudnost. To účetnictví ti řekne mnohem více o kvalitě managementu, než ti řeknou oni.”“Velké akvizice ničí hodnotu té firmy.”CO SE V PODCASTU DOZVÍTE:Začátky v investování (5:42)Jak probíhalo investování v Čechách a založení firmy Atlantik finanční trhy, a.s. (11:40)Portfolio Viktora Koženého (22:57)Zlaté časy v Atlantiku (1994) - když narrative vytváří realitu (26:15)Budování zahraniční klientely (1995 - 1996) (29:58)Boom na ruském trhu (1996 - 1997) (34:38)Objevení akcií druhé, třetí kategorie (41:50)US hedge fundy, co jely v Bernie Madoffovi (1997) (45:00)Dot.com bublina (1998) (50:11)Definice slova bublina (54:08)Prodej společnosti Atlantik finanční trhy, a.s. a působení v ABN AMRO Asset Management (Czech), a.s. (56:10)Hodnotová vs. růstová akcie (1:02:00)Argentinská lekce - měnové riziko (1:04:03)Založení Vltava Fund (2004) (1:09:28)Čínské akcie (2005 - 2011) (1:10:22)Reverse mergers (1:15:30)Vyhnutí se jihovýchodní Asie (2011) (1:19:07)Je dobré investovat do zemí, jejíž ekonomika roste? (1:21:48)Komoditní akcie a těžaři (2006 - 2008) (1:23:59)Návštěva managementu - je to správná věc? (1:29:59)Baja Mining (2007) (1:31:22)Havila Shipping (1:32:20)Sanofi a koupě Genzyme (2011) (1:34:34)Paradox shortování (2010 - 2018) (1:36:45)Tom Gayner a jeho rada investorům (2016) (1:41:24)10 největších společností na světě a jak se za poslední roky mění jejich žebříček (1:44:30)Záleží nebo nezáleží na ceně? (1:48:43)Jaké valuační metody použít? (1:56:10)Rychlost obchodování - je to skutečně výhoda? (2:02:33)Muzika, sport a investování (2:06:54) Nenechte si ujít letošní ročník České investiční konference, který proběhne 8. a 9. listopadu 2021 online. Program naleznete zde. Partnerem podcastu je Strike.Market, alternativní data pro vaše investice.Vaše zpětná vazba je pro mě důležitá. Máte-li k podcastu jakékoliv poznámky, zašlete mi je, prosím, na lenka@schanova.com. 

In this episode, Camille shares with us how her upbringing influenced her professional choices as well as her work philosophy of doing good while doing well. She also talks about her work at Venrock, what guides its investment strategy, her particular passion for investing in orphan diseases and the importance of finding the right culture at funds.

Dr. Ragan has been X4’s President and Chief Executive Officer and a member of the X4 Board of Directors since July 2014. She has more than 18 years of experience building companies in the biotechnology industry. Prior to founding X4, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc., a private biopharmaceutical company, where she led the company’s business development activities. Prior to that, Dr. Ragan held leadership roles in corporate development and operations at Genzyme Corporation, a Sanofi company, where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her B.S. from Tufts University and her Ph.D. from Massachusetts Institute of Technology and completed post-doctoral studies at Harvard Medical School.

Episode Title: How To Create A Super Bowl Ad In this episode, we talk to Tim Calkins(College Professor & Consultant) as we discuss this year's Super Bowl Ads, his book, and so much more. Be sure to check out TimCalkins.com Purchase his book How To Wash A Chicken: Mastering The Business Presentation **More On Tim** Tim is a marketing professor, author, speaker and consultant. His newest book is a guide to creating and delivering powerful business presentations. It is titled How to Wash a Chicken: Master the Business Presentation. You can read more about the new book here. Tim is Clinical Professor of Marketing at Northwestern University's Kellogg School of Management. He teaches courses including Marketing Strategy and Biomedical Marketing in the full-time, part-time and international executive MBA programs. He is also co-academic director of the Kellogg on Branding executive education program. He has received numerous awards for teaching excellence. In 2018, he received the Top Professor Award from Germany's Kellogg-WHU Executive MBA Program. He won the Lawrence G. Lavengood Outstanding Professor of the Year Award, the top teaching award at Kellogg, in 2006 and 2013, making him one of just four people in the award's more than forty year history to have won it twice. He also received the Sidney J. Levy Teaching Award, two Kellogg Faculty Impact Awards, and the Kellogg Executive MBA Program's Top Professor Award four times. Poets & Quants included him on its list “Favorite MBA Professors of 2016.” In addition to How to Wash a Chicken, Tim is the author of Defending Your Brand: How Smart Companies Use Defensive Strategy to Deal with Competitive Attacks (Palgrave Macmillan, 2012). Expert Marketer Magazine named Defending Your Brand the 2013 Marketing Book of the Year. He also wrote Breakthrough Marketing Plans (Palgrave Macmillan, 2008 and 2012). He is co-editor of Kellogg on Branding (John Wiley & Sons, 2005) and Kellogg on Branding in a Hyper-Connected World (John Wiley & Sons, 2019). Tim manages Building Strong Brands, a blog on brand strategy. Inc.com, the Web arm of Inc. Magazine, included the blog on its list of “Six Blogs That Can Teach You More Than an MBA.” He has published more than a dozen Kellogg case studies including Crestor, MedImmune: FluMist Introduction and Genzyme: the Synvisc-One Investment Decision. He has authored more than two dozen articles on marketing topics. Tim is an expert on Super Bowl advertising. He created the Kellogg Super Bowl Advertising Review in 2005 and has led the event ever since. Over the past ten years, the program has generated more than five billion media impressions. He has served as a judge for the Word of Mouth Marketing Association's WOMMY Awards, the Native Creatives Awards and the EthicMark Awards. In addition to teaching at Kellogg, Tim works with major corporations around the world on strategy and branding issues. His recent clients include Eli Lilly, Hearst and AbbVie. He is managing director of Class 5 Consulting, a marketing strategy firm. Tim is frequently cited by the media. He has been quoted in publications including Business Week, The Financial Times, The Wall Street Journal and The New York Times. He has appeared on all of the major television networks. He serves on the board of the Alliance Française de Chicago and completed two terms on the board of the Lycée Français, Chicago's French-International School. Tim began his career at the consulting firm Booz Allen and Hamilton, where he worked on strategy projects. He joined the marketing team at Kraft Foods in 1991. During his almost 11 years at Kraft, he led brands including Miracle Whip, Taco Bell, Parkay and DiGiorno. He was responsible for the launch of more than two dozen new products. He received his BA from Yale and his MBA from Harvard. Tim lives in Chicago with his wife and three children, and no chickens. Written by: Dominic Lawson  Executive Producers: Dominic Lawson and Kenda Lawson Music Credits: **Show Theme**  Behind Closed Doors - Otis McDonald  **Break Theme** Cielo - Huma-Huma  WWW.FUNKYMEDIA.AGENCY

On Episode 6 of Rosé and DNA, we spoke with population health aficionado Erica Ramos, MS, CGC! Erica is a genetic counselor and Vice President of Population Genomics at Genome Medical, a company that develops technologies, services, and strategies for delivering genomic healthcare. Before joining Genome Medical, she previously held positions at Geisinger Health, Illumina, and Genzyme. Within the genetic counseling community, she is also well known for her past leadership role as president of the National Society of Genetic Counselors in 2018 and continues to serve as an advisor for many high impact public health initiatives including the All of Us Program. Erica is a true visionary for the field and remains a fierce advocate for patients, particularly those in underserved communities. Please support the Access to Genetic Counselor Services Act (H.R. 2144)! Read more about this effort from NSGC. Spread the word about Genome Medical's Force for Good High School Essay Contest! Click here for more information. Wines tasted (and talked about!): Goulée by Cos d'Estournel - Bordeaux from Medoc region, FR Rosé All Day - 'nuff said. Twomey Cellars (California) and Lechuza Winery (Valle de Guadalupe, Mexico) Cheers! R&D

In this episode, we talk to Tim Calkins (College Professor & Consultant) as we discuss this year's Super Bowl Ads, his book, and so much more. Be sure to check out TimCalkins.com Tim is a marketing professor, author, speaker and consultant. His newest book is a guide to creating and delivering powerful business presentations. It is titled How to Wash a Chicken: Master the Business Presentation. You can read more about the new book here. Tim is Clinical Professor of Marketing at Northwestern University’s Kellogg School of Management. He teaches courses including Marketing Strategy and Biomedical Marketing in the full-time, part-time and international executive MBA programs. He is also co-academic director of the Kellogg on Branding executive education program. He has received numerous awards for teaching excellence. In 2018, he received the Top Professor Award from Germany’s Kellogg-WHU Executive MBA Program. He won the Lawrence G. Lavengood Outstanding Professor of the Year Award, the top teaching award at Kellogg, in 2006 and 2013, making him one of just four people in the award’s more than forty year history to have won it twice. He also received the Sidney J. Levy Teaching Award, two Kellogg Faculty Impact Awards, and the Kellogg Executive MBA Program’s Top Professor Award four times. Poets & Quants included him on its list “Favorite MBA Professors of 2016.” In addition to How to Wash a Chicken, Tim is the author of Defending Your Brand: How Smart Companies Use Defensive Strategy to Deal with Competitive Attacks (Palgrave Macmillan, 2012). Expert Marketer Magazine named Defending Your Brand the 2013 Marketing Book of the Year. He also wrote Breakthrough Marketing Plans (Palgrave Macmillan, 2008 and 2012). He is co-editor of Kellogg on Branding (John Wiley & Sons, 2005) and Kellogg on Branding in a Hyper-Connected World (John Wiley & Sons, 2019). Tim manages Building Strong Brands, a blog on brand strategy. Inc.com, the Web arm of Inc. Magazine, included the blog on its list of “Six Blogs That Can Teach You More Than an MBA.” He has published more than a dozen Kellogg case studies including Crestor, MedImmune: FluMist Introduction and Genzyme: the Synvisc-One Investment Decision. He has authored more than two dozen articles on marketing topics. Tim is an expert on Super Bowl advertising. He created the Kellogg Super Bowl Advertising Review in 2005 and has led the event ever since. Over the past ten years, the program has generated more than five billion media impressions. He has served as a judge for the Word of Mouth Marketing Association’s WOMMY Awards, the Native Creatives Awards and the EthicMark Awards. In addition to teaching at Kellogg, Tim works with major corporations around the world on strategy and branding issues. His recent clients include Eli Lilly, Hearst and AbbVie. He is managing director of Class 5 Consulting, a marketing strategy firm. Tim is frequently cited by the media. He has been quoted in publications including Business Week, The Financial Times, The Wall Street Journal and The New York Times. He has appeared on all of the major television networks. He serves on the board of the Alliance Française de Chicago and completed two terms on the board of the Lycée Français, Chicago’s French-International School. Tim began his career at the consulting firm Booz Allen and Hamilton, where he worked on strategy projects. He joined the marketing team at Kraft Foods in 1991. During his almost 11 years at Kraft, he led brands including Miracle Whip, Taco Bell, Parkay and DiGiorno. He was responsible for the launch of more than two dozen new products. He received his BA from Yale and his MBA from Harvard. Tim lives in Chicago with his wife and three children, and no chickens. Hectic is an all-in-one business management software built specifically for freelancers who arejust getting started or looking to take their freelance business to the next level. Sign up at gethecticapp.com/thestartuplife

Paul Brennan, President and CEO of NervGen Pharma Corp, developer of treatments related to nerve damage and neurodegenerative diseases, discusses the struggle for financial backing for the development of drugs to treat conditions such as traumatic brain injury and stroke. He compares this to the 'money' available to finding an effective treatment and cure for Alzheimer’s disease. President and Chief Executive Officer. Paul Brennan has over 30 years of experience in the pharmaceutical and biotech industries working in leadership roles in general management, corporate strategy, commercial planning, business development and regulatory affairs in Canada, Sweden, the United Kingdom, and the United States. Most recently Mr. Brennan’s experiences include senior business development and management positions in various biotech companies, including Aquinox Pharmaceuticals, Arbutus Biopharma, Aspreva Pharmaceuticals, and AnorMED Inc. Mr. Brennan has a comprehensive list of business development and licensing transactions, totaling over $3 billion in value: he played key roles in the merger of Tekmira Pharmaceuticals and OnCore BioPharma to create Arbutus Biopharma, in the sale of Aspreva Pharmaceuticals to Vifor Pharma for $915 million and in the sale of AnorMED to Genzyme for $580 million. Prior to working in biotech Mr. Brennan held senior roles in Business Development and Regulatory Affairs at AstraZeneca. Mr. Brennan holds a MSc in Physiology, and a BSc (Hons) in Life Sciences from Queen’s University in Kingston, Ontario.

Movement disorder trials have always been demanding. Now, sponsors face an additional challenge: How do you ensure data integrity in the era of remote clinical trials? In this podcast, Bob Dagher, MD, WCG MedAvante-ProPhase’s Chief Medical Officer, addresses this in conversation with Steve Smith, WCG President of Patient Advocacy. This is the fourth episode in our series, “Transforming CNS Trials During COVID-19—and Beyond.”Sponsors planning to restart movement disorder programs need to be clear-eyed and realistic, Dagher counsels. “When it comes to remote assessments, we have to be vigilant and aware of what we can do and also about what we really cannot do.” Some assessments simply cannot be performed remotely. This means sponsors will need to figure out how to account for variability and missing data in their statistical plan before locking the database.FDA guidance on the conduct of trials during COVID-19 helps provide a roadmap. For example, in the case of anticipated missing data the guidance clearly states to capture specific information in the case report form that explains the relationship to COVID-19. But it also requires in-depth scientific and clinically-informed knowledge so that the quality of the data captured isn’t sacrificed as direct result. Accordingly, WCG has been working with clients to tailor remote assessments for sponsors’ trials, yielding assessments that are as close as possible to the in-person versions (minus those particular items that cannot be done remotely).Dagher’s message? “Ensuring data integrity at every step of the process should be the primary guide for any decision-making process when deciding to restart your study.”Prior to joining WCG MA-PP, Dr. Dagher, was the Chief Medical Officer of Cadent Therapeutics in Cambridge, Mass. Before that, he served in many leadership roles at small and large biopharmaceutical and clinical research organizations, including GlaxoSmithKline, Genzyme, Sanofi and Covance, among others. Dr. Dagher has fostered the development of multiple products in different indications and development platforms and advanced several small molecules and biologics across all stages of clinical development. His background includes therapeutic experience in psychiatry, neurology and rare diseases.

This episode is sponsored by Davwill Consulting Inc. - Looking to review your team?Rob Greenly is a savvy, experienced executive coach and organizational effectiveness consultant. He draws upon twenty years of corporate experience and ten years as a coach and consultant to help his clients maximize their leadership and organizational potential. He applies expertise in leadership coaching, communications, conflict negotiation, team building, performance management, culture & organization change, and training to achieve consistent success for clients. Clients give Rob rave reviews for coaching them—and facilitating their teams—to navigate successfully in large, complex organizations. He draws upon his own firsthand experience as a senior leader and shares lessons-learned from his tenure as Vice President of Leadership and Organization Development—Boston Scientific, Director of OD and Training—Astra Pharmaceuticals, Director of Leadership at the MIT Sloan School of Management, and Chief Administrative Officer for Human Resources—Putnam Investments. Rob has provided executive coaching and/or has developed and delivered programs in management, leadership, team building, organization development, and competency modeling with pragmatic applications, for a wide-range of biopharma/healthcare/medical device clients, including AstraZeneca, Biogen Idec, Covidien, Genzyme, Harvard-Vanguard Medical Associates/Atrius Health, The Medicines Company, Millennium Pharmaceuticals, Novartis Institutes for Biomedical Research, Schering-Plough, and UMass Memorial Medical Center. Also, Rob has coached or consulted to CVS/Pharmacies, General Electric, Harvard University, IBM, Liberty Mutual, Merrill Lynch, National Institutes of Corrections, Northeastern University, the US Navy, and others.Rob's Website - http://www.greenlygroup.com/--- Send in a voice message: https://anchor.fm/deb-crowe/message This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit debcrowe.substack.com

My guest today is Prof Charles Cooney. Prof Cooney received his B.S. in chemical engineering from the University of Pennsylvania in 1966, and the S.M. (1967) and Ph.D. (1970) in biochemical engineering from MIT. He joined the MIT faculty as an assistant professor in 1970, becoming full professor in 1982. Prof Cooney's honors include the 1989 Gold Medal of the Institute of Biotechnological Studies (London); the Food, Pharmaceutical, and Bioengineering Award from the American Institute of Chemical Engineers; the James Van Lanen Distinguished Service Award from the American Chemical Society's Division of Microbial and Biochemical Technology; and election to the American Institute of Medical and Biochemical Engineers and the Fellows of the American Chemical Society. A consultant to multiple biotech and pharmaceutical companies, Prof Cooney has served on the boards of Genzyme, Polypore International, and Biocon, Ltd. (India), among others. His research and teaching span many aspects of biochemical engineering and pharmaceutical manufacturing. He holds more than 30 patents, has published over 250 research papers, and has co-authored or edited five books, including Development of Sustainable Bioprocesses: Modeling and Assessment. In addition to his professional interests, Prof Cooney is a trustee of the Boston Ballet, an overseer of the Boston Symphony Orchestra, and a board member of MIT's Community Service Fund. Other interests include rock climbing, skiing, high altitude mountaineering, scuba diving, and antique map collecting. He's a man of many talents and interests. In this interview, we're talking about all of this and much more. Here's Prof Cooney.

Soulaima Gourani is a Young Global Leader of the World Economic Forum, and the owner of tradeconductor.com and womenreignite.com In this episode of ‘Mind, Money & Body’ Podcast, Gouraima shares her inspiring story as a global leader. Gouraima is a Danish Moroccan corporate advisor, speaker and writer based in Palo Alto, California. Key takeaways: Keep working towards your goals relentlessly. Keep learning and stay inspired. Learn from books, videos and various other resources. Adopt a helping attitude and support others too, in achieving their goals. Not everyone has access to resources and same level of privileges. Visit: https://womenreignite.com Read her book: https://bookboon.com/da/ignite-your-career-ebook Subscribe to the Podcast: http://marcom18.libsyn.com/success-against-all-odds She has authored several bestseller books on themes like “How to take control over your life” and “How to Design Your Future” and many others. She has worked with clients as Samsung, Roche A/S, Leo‐Pharma, NNIT, Genzyme, Aberdeen, DuPont, LEGO, McKinsey, DELL, Microsoft, Adecco, ManSoft, Alk Abello, Aon Hewitt, Citroen, Colliers, Diageo, Cisco, Ernst & Young, Volvo, FL Smidth, H. Lundbeck, IBM, TDC, SimCorp, Novo Nordisk, Novozymes, Danske Bank, News Corp and Deloitte etc. Her geographic experience includes 35+ countries: Denmark, Norway, Sweden, USA, Finland, Greenland, Austria, Hungary, Germany, UK, France, Italy, Saudi Arabia, Israel, Russia, Mongolia, Dubai, Sri Lanka, Myanmar, India, Greece, Thailand, Egypt, Venezuela, Morocco, Turkey, China, Lebanon, Japan, Switzerland, Mexico and Bahrain. She is a keynote speaker and an advisor to major companies on customer loyalty, strategic networking, change management, employee motivation and future of business. Subscribe the Podcast now to receive more such insightful content about financial, mental and physical well-being. Thank you. Vikram Jethwani Digital Strategist & Founder – Marcom18 www.marcom18.com --- Send in a voice message: https://anchor.fm/vikram-jethwani/message

Jason and Matthew interview Dr. Harold Punnett (co-founder and member of the Board of Directors) and Paul Brennan (President and CEO) from NervGen Pharma. They discuss how Dr. Punnett’s daughter-in-law’s Spinal Cord Injury led to the connection with Dr. Jerry Silver (click the link to hear more about the science from episode 19 with Dr. Jerry Silver) and eventually the founding of the company, their proprietary NVG291 (also known as intracellular sigma peptide or ISP) and their hopes for its use in treating SCI and other CNS disorders. Dr. Harold Punnett: Dr. Punnett, co-founder of NervGen, is an accomplished angel investor who has been the director of multiple start-up companies. As a dental surgeon with a practice in British Columbia, Canada, he has extensive knowledge of medicine and physiology, including cell biology. Along with this knowledge, he has a deep passion for those suffering from spinal cord injury and other nerve-related challenges. Dr. Punnett is a Member of the College of Dental Surgeons of British Columbia, Member of the British Columbia Dental Association and Member of the Canadian Dental Association. He received his doctorate degree from the University of British Columbia. Paul Brennan: Paul Brennan has over 30 years of experience in the pharmaceutical and biotech industries working in leadership roles in general management, corporate strategy, commercial planning, business development and regulatory affairs in Canada, Sweden, the United Kingdom, and the United States. Most recently Mr. Brennan’s experiences include senior business development and management positions in various biotech companies, including Aquinox Pharmaceuticals, Arbutus Biopharma, Aspreva Pharmaceuticals, and AnorMED Inc. Mr. Brennan has a comprehensive list of business development and licensing transactions, totalling over $3 billion in value: he played key roles in the merger of Tekmira Pharmaceuticals and OnCore BioPharma to create Arbutus Biopharma, in the sale of Aspreva Pharmaceuticals to Vifor Pharma for $915 million and in the sale of AnorMED to Genzyme for $580 million. Prior to working in biotech Mr. Brennan held senior roles in Business Development and Regulatory Affairs at AstraZeneca. Mr. Brennan holds a MSc in Physiology, and a BSc (Hons) in Life Sciences from Queen’s University in Kingston, Ontario

WHIM syndrome is a rare, inherited, primary immunodeficiency disease caused by mutations to the CXCR4 receptor gene. Because of the role CXCR4 plays in the immune system, it is implicated in a number of rare diseases. X4 Pharmaceuticals, a company founded by rare disease pioneer Henri Termeer and other Genzyme alums, is developing a pipeline of CXCR4-targeted therapies. We spoke to Paula Ragan, co-founder, president and CEO of X4, about WHIM syndrome, the role CXCR4 plays in the immune system, and how the company’s experimental therapy Mavorixafor may be able to treat a range of rare conditions.

This week’s guest is an amazing corporate trainer, Rob Sullivan! In this episode we're covering: What language to use to close any deal How to coach underperforming to performing employees Top tips for managerial success And so much more!! Rob Sullivan is an author, inspirational speaker and corporate trainer who has delivered workshops and keynotes at companies, universities and trade associations internationally. In addition to delivering workshops in the U.S., Canada, and Mexico for a long list of clients including Facebook, Goldman Sachs, Genzyme, and Ace Hardware, Rob has received high praise for his work with JP Morgan Chase in the U.K. In addition, he was selected to lead a workshop in London on the topic of energy, communication, and charisma for an audience of trainers from all over the world. Rob recently expanded his international reach in a partnership with Josseline Ross and Barry Van Zyl, the drummer for Johnny Clegg, the legendary South African musician who has sold 5 million albums and inspired Paul Simon’s Graceland album. Rob and Barry will be piloting a workshop in London and South Africa that incorporates music, creativity, communication, and collaboration. Rob was inspired to create the workshop to combine what he learned as a communication coach with the insight he gained from both on-camera acting and improvisation classes at Second City in Chicago, the training ground for Bill Murray, John Belushi, Dan Akyroyd, and countless others. Rob has an M.S. in Advertising for Northwestern University's Medill School of Journalism and a B.A. in Psychology from the College of the Holy Cross in Worcester, MA. Selected Achievements • Featured in the Wall Street Journal and as a repeat guest on NBC, ABC, and WGN • Guest sales expert on Starting Over, an Emmy-award winning reality show that aired nationally on NBC from 2005 to 2007 • Delivered four commencement speeches to audiences over 1,200 • Hired as a speaker 28 times by Northwestern University alone • Author of the book Getting Your Foot in the Door When You Don’t Have a Leg to Stand On (McGraw-Hill, 4 printings) • Author of the forthcoming book Signposts on an Inner Expedition: Trusting Your Internal GPS (working title) Reach out to Rob at the following links: www.sullivanzy.com www.signpostsbook.com Let us know how you like it. Rate us. Leave a comment. Email us at info@abundantculture.co. Do something! To learn more about the training mentioned, click the following link (and mention code: MIMS) at checkout: https://profitarchitects.com/ Connect with us at: IG: @abundant.culture FB: @abundantculture Rate us on your favorite podcast platform! Join our newsletter: https://www.abundantculture.co/

Our 2019 Cade Prize winners, Greg Hudalla and Ben Keselowsky, have invented a new way to control inflammatory diseases such as arthritis. The method uses natural enzymes to suppress inflammation at the source, without the harmful side effects of medications. Ben, a native of Tampa and a graduate of the University of South Florida, always enjoyed science and math and was inspired by his high school physics teacher. Greg, originally from Chicago, became interested in medicine after a serious knee accident at 18 ended his collegiate athletic career. *This episode was originally released on May 22, 2019.* TRANSCRIPT: Intro: 0:01 Inventors and their inventions. Welcome to Radio Cade a podcast from the Cade Museum for Creativity and Invention in Gainesville, Florida. The museum is named after James Robert Cade , who invented Gatorade in 1965. My name is Richard Miles. We’ll introduce you to inventors and the things that motivate them, we’ll learn about their personal stories, how their inventions work and how their ideas get from the laboratory to the marketplace. Richard Miles: 0:39 Weekend warriors rejoice, your bad knees are about to get better. That is if the breakthrough by our guests today becomes widely available. People suffering from arthritis will have a brighter future. And before I mangle any more metaphors, welcome my guests, Greg Hudalla and Ben Keselowsky, both professors in biomedical engineering at the University of Florida. Welcome Greg and Ben . Ben Keselowsky: 0:57 Hi. Greg Hudalla: 0:57 Hi. Richard Miles: 0:58 So this is actually personal for me because I’ve been a lifelong runner and just last year found out I have osteoarthritis, a word I couldn’t even pronounce six months ago, much less define. So in between icing my knee and stretching, spending a lot of time at the physical therapist office, I come across your application of the Cade Prize. And so after the show, you’ll both lay hands on me and I’ll be good to go, right? It’s simple, a few needles might be evolved , right ? So let’s explain for our listeners in simple terms, what is the problem that you’re trying to solve? And how does your invention do that? Ben Keselowsky: 1:29 Our mission is to control inflammatory disease and we’re motivated by the fact that inflammation underlies the onset, the progression and the pain associated with numerous diseases that affect millions of people. And so osteoarthritis is one of these that we’re particularly interested in, in the U.S. 13% of the population is afflicted. That’s over 40 million people with direct healthcare costs of over $80 billion per year. Current technologies include steroids and antibodies, and they’re injected into the bloodstream and they’re distributed throughout the body. And they’re associated with terrible side effects, including infection, lymphoma, diabetes, and weight gain. And our technology works at the site of inflammation and it uses natural mechanisms that suppress inflammation. And so, we use an enzyme called IDO, Indoleamine dioxygenase, it breaks down an essential amino acid, tryptophan, into its product [inaudible] . And those two mechanisms, the local depletion of tryptophan and production of [inaudible] work together to quiet down inflammation. And so being able to suppress that inflammation allows tissue to return to healthy function. Greg Hudalla: 2:51 So the key challenge for us when we began developing this technology was coming up with a strategy to place IDO at the site action and have it persist There for a useful duration of time. Um , so if you were to say, inject the drug directly into the tissue of interest, it would be gone within minutes to hours. So you don’t really get a lot of activity or efficacy from a drug. Richard Miles: 3:14 Greg, if I can interrupt that’s the current standard of care, right? That’s what most people do though. They’ll go in, for instance, with osteoarthritis, they’ll go in to get a shot of what is a cortisone or something like that, right? Greg Hudalla: 3:22 Right.Yeah, so they’ll either get a topical treatment right on the surface of the skin, in which case the steroid can penetrate into the joint and have some effect, or they’ll get a localized injection, or they’ll have say an intravenous infusion of drug that’s coursing throughout the entire body. So, what we sought to do was develop an approach by which you can inject the drug into the tissue site, and it would persist as opposed to diffusing away and losing action at the site of interest. So to do this, we developed a technology that we’ve dubbed GATOR, which stands for Galectin Anchors for Therapeutic Enzyme Retention. Specifically, we link IDO our therapeutic enzyme to galectin three, a protein that binds to sugars that decorate every tissue within your body by binding to tissue sugars. Galectin three anchors IDO at the site of injection. So this prevents the diffusion of the drug through the tissue. And this gives us a much longer duration of action of drug at the site of interest. So for example, our version 1.0 of IDO GATOR persists at the injection site for upwards of seven days. Whereas again, conventional drugs say if we were to inject IDO into the tissue directly, it would be gone within minutes to hours. So in terms of moving the technology forward, we have demonstrated preclinical efficacy of IDO GATOR, and a couple of models. So the first is osteoarthritis as was alluded to at the onset of our show today. Um, in these cases, we’ve been able to demonstrate that injection of IDO GATOR into the joint that’s afflicted with osteoarthritis will reduce pain that’s sensed by the host. It will also tamp down inflammation, which in turn will prevent further progression of the disease. And a striking sort of observation here is that injection of IDO GATOR can restore normal gait in the patients . So a patient that’s experienced some degree of limping that limp will be diminished following injection of the drug into the joint. The other space where we have really exciting data is in the area of periodontal disease. So a non resolving chronic inflammation in a tooth. And what we’ve demonstrated to date is that by injecting IDO, IDO GATOR into the site of disease, that again, we can suppress inflammation as a result of turning down that inflammation. We can prevent the bone loss, that’s a hallmark of the disease, which would ultimately lead to the need for the tooth to be extracted or removed. So by getting ahead of the inflammation, we’re not getting ahead of the disease progression Richard Miles: 5:42 So far, I’m loving this. I mean, it sounds like great news. And I neglected mention at the top of the show that to , to congratulate you on advancing from the Cade Prize, sweet 16 round to the final four round. So congratulations to both of you. -Thank you very much. Tell me, does your current research indicate, is there the possibility that you could extend this even beyond say seven days? And is there also the possibility that you mentioned there would be like in the case of say knees, injections, is there a topical patch or application possibility in this? Greg Hudalla: 6:11 Yeah, so I’ll touch on the first question, which is, is there a way to extend the duration? So we haven’t demonstrated it yet with IDO G, but we have developed a model platform in which we can achieve residence time or duration of action, upwards of about 14 to 17 days at the injection site. So in order to do this, we play sort of a biochemistry trick. So most of your listeners are probably familiar with Velcro, right? And Velcros two material surfaces that interact through a series of hooks and eyes, right? And if you were in a vision , one hook interacting with one eye, you can pull it apart pretty easily, but as you start to link multiple hooks and eyes together, you significantly strengthened the interaction at that interface, the interaction between the two pieces of Velcro. So what we do essentially, as we increase the number of galectin three binding sites, and we take our protein of interest or therapeutic interest say IDO, and now, instead of linking it to one copy of our galectin three anchor, we can link it to two or three or four copies of our collecting three anchor. And so this acts in a census molecular Velcro now, instead of having one site of interaction, you have multiple sites of interaction by adding these sites of interaction together, you can strengthen the anchoring phenomenon that we see occur. And so again, we can go from our flagships seven day formulation to formulations that should persist for weeks at the injection site . Richard Miles: 7:29 So before we talk about the commercial path that you’d like to see this travel, let’s talk a little bit about the approval process, right? Because what little I know of medical drugs of any sort of medical devices, there’s this very long convoluted FDA approval process that lasts like 100 years, right ? Roughly right . Maybe 98. It’s just going to be tough to get through the approval process. Ben, you want to take a stab at that? Greg Hudalla: 7:49 So as you mentioned, this would classify as a drug. And so with that comes some unique challenges in the FDA translation space. So first maybe a bit of history. So our therapeutic is an enzyme and enzymes are actually the first class of proteins that were pursued as biologic drugs. So as early, as about the 1950s, when scientists first started developing a real handle on what enzymes do and the roles that they play, and then being able to extract them from living systems, they were really attractive drug candidates because they catalyze reactions they’ll speed, a reaction up they’re essential for basically every biological reaction that happens in our bodies. And so the idea is that unlike a small molecule in which you deliver a very high dose, in principle, you can deliver a little bit of enzyme and it will go a very long way because it will continue acting on drugs fast forward about 30 years into the future, and enzymes have been outpaced by biologic drugs that we hear a lot more about. And some things like monoclonal antibodies. And the reason why is because of the fact that a little bit of enzyme goes a long way. If they leave the site of intended action, they can catalyze reactions offsite, and this can lead to unwanted side effects. So again, that was one of the major drivers behind our anchoring technology now onto the sort of translational efforts or the , what we see as the translational path for IDO GATOR, one of the benefits of our system. So let me remind everyone that what our technology is really based on is what we know of sort of a peanut butter and jelly or chocolate and peanut butter. We take a really promising enzyme drug, and we link it to this anchoring domain, galectin three. And so we’ve taken two proteins and we’ve physically stuck them together to make a new molecule , um , on some level that presents a series of challenges. But the benefit here is that IDO is a protein that’s expressed within our bodies . So we’re naturally tolerant to that enzyme being around galectin three is also a protein that is expressed within our bodies. So we’re naturally tolerant to galectin three being around. So we envision from a safety profile, that IDO of galectin three will be relatively safe from the perspective of it’s tolerance by your immune system. The other benefits of our system that sort of speak to this safety features are that because we’re delivering IDO GATOR locally, we can significantly reduce the dose. So even if a little bit of drug does leave the site of intended action and get into circulation, move into another tissue, the amount of enzyme that’s, there is so low that it’s unlikely to have significant side effects that one might experience if they were to deliver the same drug systemically. So, from the perspective of the molecule itself and sort of entry into the human space, we see those as being real advantages. There’s one more unique feature of our technology that I want to touch on too , which sets it apart from a lot of biologics that go through the preclinical pipeline and then try to make the transition into the clinical or human use space. And that is that galectin three, the anchoring domain in our technology interacts with sugars that are decorating human tissues, but these sugar molecules are conserved from mouse to man. So what that means is , is in principle, there will be no re-engineering of the drug that’s required. So your listeners may have heard of humanized antibodies in the past. So this is an antibody that’s raised in an animal host. And then the domain that’s necessary for binding to sites in our tissue is maintained. It’s moved over from the animal antibody into a human antibody to make it safer, make it more tolerated within human systems. We wouldn’t need to go through that process. So we see on one level, a clearer translation from the preclinical studies that we’re doing now into the clinical space, but we also see this as another potential business opportunity. And that is that we could in theory, use this same therapeutic in veterinary medicine applications. So osteoarthritis, periodontal disease, the two spaces in which we’ve been evaluating efficacy now , um , are things that afflict companion pets all the time, right? My dogs have had teeth extracted because of , of periodontal disease. And I know of a significant number of friends who have dogs and cats that’s that have experienced osteoarthritis in their hips and their knees. As they get older, they receive a lot of the same conventional treatments that humans do, injections of steroids or injections of antibodies because of the fact that both IDO and the galectin three anchoring domain are conserved across mammalian species and the mechanisms by which they work are conserved across mammalian species. We really think there’s an opportunity here to translate into the vet product space first, and then use that to really springboard into the human clinical use. Richard Miles: 12:13 So let’s talk about the business side a bit. Now, could you describe for me what sort of your game plan is now? I mean, are you both going to quit your jobs? One of you clean out your garage? You’ll be for like Steve Wasnic was next Steve jobs, right. You’ll be mixing enzymes in the basement or is there a different, a better path available? Ben Keselowsky: 12:27 Yeah. So this gets into the question of what is it that people should do when they’re trying to start a new company, and it’s really about finding the right team. So finding the right team members and that’s where we’re at. So, we are looking for business people. We’re looking for investing partners to really help drive this forward with vision, with experience. This is the stage we’re at. We’re trying to find partners to help drive this forward. Richard Miles: 12:54 Oh , so still very early stage. Do you have patents on this technology? Ben Keselowsky: 12:57 We’re pending. Yes, we do. We’re very lucky to have excellent support from the office of technology licensing here at UF, and we are pursuing patents in U.S., Canada, Europe, Japan, and Australia and Australia. Thank you. Richard Miles: 13:11 So one of the things our listeners find interesting, at least I find it interesting is the personal backgrounds of the inventors that we have on the show. So Ben, maybe starting with you, if you could talk a little bit about where you’re from, what were some of your early influences? How’d you end up in North central Florida doing some research? Ben Keselowsky: 13:26 Sure. Yeah. So I am born and raised in Florida from Tampa. Richard Miles: 13:31 So you’re a long way from home, right? Ben Keselowsky: 13:33 95 miles or something. That’s right. So growing up in Tampa, I went to USF and studied there. And then I moved all the way up North to Atlanta for grad school and then moved back down to Tampa. So I was, Richard Miles: 13:44 Winters were too cold for up there? Ben Keselowsky: 13:45 Yes, they dragged on and on in Atlanta. So I was very happy to get my family close. We love the small college town. You have mentioned. We were just across the street at the festival. And so we enjoyed the small college town and UF is a fantastic place to be. Our department is centrally located with the health sciences, the teaching hospital, the veterinary medicine, the rest of engineering. We have a really great location where we are in . Fantastic. Richard Miles: 14:13 Did you always want to go into an engineering or science related field? What were you like as a kid? Were you a good student? Teacher’s pet? Spill the beans here. Ben Keselowsky: 14:20 I really quite enjoyed science and math. And my dad was a retired mechanical engineer, worked at TECO Tamp Electric Cooperative. He’d take me to the power plant and show me the boilers and everything that , how it works and teach me how combustion engines work. So, yeah, I was pretty nerdy and enjoyed things like that. It was basically told I’m doing well in this. I should think about engineering. That was your parents telling you that teachers telling you that was my father. Um, and actually in high school, I looked up to my physics teacher a lot. He was fantastic. Terry Adams, he made things very fun. And the group in the class had a lot of fun trying to learn these concepts together and really enjoy the creativity and the teamwork, which is fantastic. Greg and I came together on this chocolate and peanut butter concept just by chatting because we’re right next door . Our offices are running door to each other, but growing up, I was kind of did well in math and science and enjoyed it a lot. I enjoyed the arts too, but now kind of my outlet is the creativity with science and technology. Richard Miles: 15:27 Greg, your turn, were you the sort of kid that we’re dissecting frogs when you’re three years something, tell us about your upbringing. Greg Hudalla: 15:33 So I grew up in and then just outside of Chicago. So I’m a bit farther away from home. I did my undergrad at the Illinois Institute of technology and then grad school in Wisconsin so much like Ben made a pretty short commute from home. And then I moved back to Chicago and my entire family, my entire extended family is still in the greater Chicago land area. So when I left for Madison and then came back, they thought, all right , you’ve done it. You’ve seen the world. You know , there’s Chicago, it’s the greatest city on earth. Richard Miles: 15:57 Wisconsin, how much further can you go? I mean come on. Greg Hudalla: 16:00 And then , uh , Ben was on the hiring committee when I was applying for jobs and University of Florida popped up on my radar. And you could sort of hear the needle scratch if you will, or the tire squeal in the minds of all of my family members, as I tried to explain to them that we were going to pick up and move to Gainesville, but you know, it’s been great. It’s a quintessential American college town and it’s been a really terrific experience in the few years that I’ve been here. So getting back to a little bit of my sort of pre academic time. So I was always a good student, but when I went to college, I didn’t really have a clear vision of what it was that I wanted to do. So, I’m the son of an iron worker and a court reporter. And for them, college was a big deal putting my brother and I into school and seeing us through to the finish line was a huge deal for the two of them. But I was flexible. And like I said, sort of lacking vision when I first went to college. And so my freshman year I was actually a college athlete. So I was playing on the university soccer team and three games into my freshman year. I suffered an injury to my knee that resulted in a significant amount of cartilage. So damage on the, about the size of a silver dollar cartilage had detached from my femur. So I’m in 18, 19 year old kid. At this point in time, I went from pretty much not having osteoarthritis to having extremely advanced osteoarthritis, Richard Miles: 17:16 So this really is personal for you. Greg Hudalla: 17:17 30 seconds. Right? And so when we went to the orthopedic surgeon, the suggestion at the time was we have to take the cartilage out and we’re probably going to need to give you a total knee replacement. And again, I’m a 19 year old kid at this point in time, Richard Miles: 17:30 Not the typical knee replacement surgery candidate . Greg Hudalla: 17:32 Exactly. Right? And this is the early two thousands when total knee replacements don’t have a particularly long lifespan . And so insurance wasn’t happy. My parents weren’t happy. I wasn’t happy. The surgeon wasn’t happy. And so initially they had done a microfracture procedure to try and restore , uh , send me the cartilage that was still relatively healthy at the site. And some time was put into, let’s try to find an alternative approach, some other way to deal with this. And so maybe six to nine months later, we’re meeting with the orthopedic surgeon. And he says, I think you’re a good candidate for a brand new technology. It’s technology known as Carticel that was pioneered by Genzyme in which they take a biopsy of cartilage cells from a healthy site in your body. And they send them out to a lab. They grow them up and they reimplant those cells back into your tissue . So it’s a way to save the joint, save the bone, and ideally provide me a longer timeframe before I might need a total knee replacement. Now I’m 18 or so 19 years out from this procedure. And I still have my original knee, but it was at that moment, that was when the light bulb went off for me. And I said, I want to know who does this right? Who develops technologies like this ? What career path do you follow? Where you can work on things where you can have this sort of impact on someone’s quality of life. And that was when I was introduced to the world of biomedical engineering. And from that moment forward, I said, this is what I want to do. I’m going to study engineering, go to graduate school. And ultimately I want to be running my own academic research lab somewhere. Richard Miles: 18:55 Wow, that’s an amazing moment of clarity for an 18 year old. So refresh my memory. This would result of a hit on the field, or how did this happen? Greg Hudalla: 19:02 Yeah, so I, Richard Miles: 19:03 So you need to go back and thank that guy who took you out, right? Like, oh he gave me direction. Greg Hudalla: 19:07 So it was me that, you know, the fault is entirely on me. I remember going in for the slide tackle and feeling the moment of pain and thinking, this is it, this is what’s happened. What’s going on. It was a game changing experience. Richard Miles: 19:17 So the two of you are still in the thick of your academic careers. And I realized I have to talk to you . You’re you’re older than I thought you were. I think part of it’s by the time you hit your mid fifties, everybody looks young, right? So I was going to say, well, you don’t have much experience to share, but clearly you actually do, in terms of wisdom for younger academics or younger entrepreneurs. And you probably have already gotten this question or you certainly will get it more and more. And that is how did you do it? You can tell us a secret of taking a research and commercializing it. And I understand you’re still at the very beginning of that path, but what are some of the lessons you feel you’ve learned already being in academia for a good while now, and as you see the transition, perhaps of either a new life or a new path for your research commercial market, what are the sorts of things that you would do again, Ben, we can start with you and what are the things that you would not do again? Ben Keselowsky: 20:03 So right now, what we’re trying to do with this technology is very early. And so really the advice of team building is paramount finding the right people. We’re still making those efforts. And so the Cade contest has been fantastic and it’s motivated us to really push on that more and more, and to keep going out for more and more activities like that. And I think that’s just expanding your contact base and trying to make more and more interactions until you find just the right match. So in this venture, we’re still working on that. I’m trying to answer your specific question . Richard Miles: 20:41 Okay. Anything else you want to dispense wisdom on? And just life advice, you know, you don’t have to come up with the smart answers, but it’s funny. Sometimes people have had either very positive or sort of horrific experiences along the way, but it sounds like you all have had a fairly stable, happy research careers to date. Ben Keselowsky: 21:02 It’s a lot of work, keeping your head up, having a group of people that you can rely on to keep you going and commiserate with is critical. So on the commercial side, I’m also a cofounder of a small company called One Vacs LLC. And they’re still also working on finding the right business partners and investors and things like that. They have been quite successful with the people that have been working there. Greg Marshall, is he person there and he’s been getting SBI. Ours is getting NIH funding through small business grants. So I think that that’s a fantastic pathway that startup companies can take as well. But it’s independent from finding the right business partners and you have to do both those things to be successful. Richard Miles: 21:47 Greg how about you, aside from going out and getting banged up on the sports field as a path to advancement, what else would you share in terms of lessons learned? Greg Hudalla: 21:54 I think a lot of us approach this with a vision of what we want to do. There’s a finish line there. And I think the important part is figuring out how to move along that path. Really the first step in that process is identifying the technology. So I’ll be the first one to admit when I started my academic career, I had no idea that this is where my research was going to go at galectin three and galactans are a family of proteins that I’ve studied in my research for a number of years now. But it really wasn’t until a day that I remember very fondly of leaning against the door jam of Ben’s office. And him kind of complaining to me and me complaining about various things. And he said, I’ve got this enzyme that I think is a really terrific candidate for therapeutic. I just don’t know how to get it where I want it to go. And he said, could we do something like this? Could we modify it in this way or modified in that way? He’s like all of my conventional approaches have tried and I just keep destroying the enzyme. I can’t maintain its activity. And I was just kind of standing there daydreaming. And I remember saying, well, we work with on this family of carbohydrate binding proteins, nobody’s really asked if we could use this as a way to localize it a protein at a site of interest. Let’s take a shot at this and see what happens. And now, you know, we’re three or four years down the road. We not only have demonstration that the concept works, but we’ve started moving it into developing this new drug that we think actually has potential to impact the quality of life of many people, the world over. And so for me, that’s the thing that I would encourage people to not lose sight of the opportunity that’s in front of you and listen to the people around you and take what you know, and try to find ways to move what you know, into new spaces. That’s really what innovation is, right? It’s not about inventing something new from scratch, right? I had a student a number of years ago, use the analogy of putting wheels on a suitcase for many years, we lugged suitcases around. So your cases are fantastic tool. As soon as someone put wheels on the suitcase, right? That innovation of taking two technologies that have been around for a very, very long time and blending them together. It revolutionized the way that we travel for me, that’s at the crux of really doing something interesting and exciting and novel. It’s not about finding something fundamentally new it’s on some level, taking things that already exist and finding ways to repurpose them and opportunities to interact with amazing colleagues like Ben and the other people around me at UF have opened my eyes to opportunities that again, when I started my career, I didn’t have the foresight and I didn’t know that this was what my path would look like. Richard Miles: 24:18 So you guys are gonna have to remember and write down these origin stories. Cause after you’ve sold Gator for billions of dollars, you both have yachts and multiple houses gonna need some sort of anchor of humility and touching Greg and Ben. I can already tell there’s a great team dynamic here. I think you guys are gonna do quite well. And thank you very much for coming on Radio Cade, I hope to have you back as guests for an update. Ben Keselowsky: 24:38 Thank you so much. Greg Hudalla: 24:38 Yes. Thanks a lot. Richard Miles: 24:40 I’m Richard Miles. Outro: 24:43 Radio Cade would like to thank the following people for their help and support Liz Gist of the Cade Museum for coordinating and vendor interviews. Bob McPeak of Heartwood Soundstage in downtown Gainesville, Florida for recording, editing and production of the podcasts and music theme. Tracy Collins for the composition and performance of the radio Cade theme song featuring violinist, Jacob Lawson and special thanks to the Cade Museum for Creativity and Invention located in Gainesville, Florida.

Few megadeals within the past decade have received as many recurring kudos as the acquisition of Genzyme, of Cambridge, MA by France’s biggest pharmaceutical company, Sanofi. The marriage of Sanofi and Genzyme appears to have exceeded expectations, allowing all of those involved in minting the newly merged entity to rightfully keep a feather in their postmerger caps. Thus it was for Mike Kaseta, who in the wake of the merger found himself tasked with integrating the finance and IT functions of the two companies. “It’s probably the achievement that I’m most proud of in my career,” explains Kaseta, who, after nearly a decade climbing the finance ranks inside Sanofi, exited the giant pharmaceutical company to stake a claim inside the realm of early-stage biotech, where today he is CFO of Aerami Therapeutics. Looking back, Kaseta believes that the greatest lessons he gleaned from the Sanofi–Genzyme merger were people-related: “There was no iron fist. We listened to employees. We understood. In the end, we had no control deficiencies, no comments from our external auditors, and the integration occurred in a timely manner.” Looking forward, Kaseta says that raising money now tops his list of CFO priorities at Aerami. “We have to get our story out,” he adds. “We have to get it out to the right people and really engage with investors, allowing them to get as excited about our story as we are.” –Jack Sweeney Do you want to learn more about the experiences that shaped today’s finance leaders? GO PREMIUM with CFO Thought Leader and each quarter we will ship you our CFO Thought Leader Quarterly Magazine featuring profiles of 25 different CFOs (4 issues, per yr.). What’s more, become a PREMIUM member before February 1, 2020 and we’ll ship you THE CFO Yearbook 2020  featuring 100 CFO profiles. Go Premium today learn more

DNA or deoxyribonucleic acid, is perhaps the most well-known biological molecule. DNA is present in all forms of life on earth. Essentially, every cell in our bodies contains DNA or the genetic instructions - or code - that makes us what we are. DNA has a unique double helix shape, like a twisted ladder and carries these instructions or code for the development, growth, reproduction, functioning and health of all life. Remarkably, if all of the DNA in a human body was unraveled, it would reach to the sun and back more than 300 times. The code in DNA is determined by the order of the four nucleotide bases that make up DNA, adenine, cytosine, guanine and thymine and is the complete set of genes and is called a genome. As the National Human Genome Research Institute works to unlock the secrets of the human genome, researchers continue learning that nearly all diseases that we face have a genetic component. Some diseases are caused by mutations that are inherited from parents and are present in an individual at birth, like sickle cell disease, for example. Other diseases are caused by acquired mutations in a gene or group of genes that occur during a person's life. Such mutations are not inherited from a parent, but occur either randomly or due to some environmental exposure like pollutants. Today’s guest is working tirelessly to create therapies to treat genetic diseases. Specifically, Monogenic diseases. As defined by the World Health Organization, Monogenic diseases result from modifications in a single gene occurring in all cells of the body. Though relatively rare, they affect millions of people worldwide. Researchers estimate that over 10,000 of human diseases are known to be monogenic. Pure genetic diseases are caused by a single error in a single gene in the human DNA. As you can gather from my brief description, working to treat genetic diseases is complicated, demanding work and requires the commitment and intellectual power of people who are dedicated to finding answers. Today’s guest Scott Sneddon is one of those people. Scott is the President & CEO of Sharp Edge Labs. He is an entrepreneur and scientist trained in chemistry and biology with an emphasis on computational methods. He holds a Ph.D. in Chemistry & Biophysics from Carnegie-Mellon University, a J.D. from Columbia University Law School and has over 20 years of experience in the drug discovery industry, having held leadership positions at Pfizer and Genzyme. At Pfizer Dr. Sneddon was a member of the New Leads Discovery group under innovator Fred Vinick. He then went to Genzyme with Fred to help establish Genzyme's small molecule drug discovery program. There he led the Assay Development and High Throughput Screening group and was a pioneer in implementing high-throughput functional cellular assays for primary drug screening (before such a thing was fashionable).

Epsiode 205: HR Maven Sofia Kaufman, veteran of companies like AOL, TripAdvisor and Genzyme, joins Ed to expose the pluses, minuses, undeniable truths and evil underbellies of the world of Human Relations. Find Sofia at https://www.linkedin.com/in/sofia-kaufman-8aa5974/

In this conversation, I chat with Samantha Truex, a Dartmouth alum and accomplished professional within the biotech space. In this conversation, we get a sense for what has driven Samantha towards a career at the intersection of technology and science, what she's been able to accomplish, and the universe of opportunities that exist for those who may also be interested in the biotech space.

Ralph Kern, MD, MHSc, is Chief Operating Officer and Chief Medical Officer at BrainStorm. He brings significant industry and neurodegenerative disease experience to the organization. His biotech experience includes senior medical roles at Genzyme, Novartis, and Biogen. At Novartis he was Vice President and Head of the Neuroscience Medical Team, leading the global launch of Gilenya® in relapsing remitting multiple sclerosis (rrMS). At Biogen he was Senior Vice President and Head of the Worldwide Medical Organization. His team launched Zinbryta® in rrMS and Spinraza® in spinal muscular atrophy (SMA), and developed the medical and scientific strategy for MS, SMA, and Alzheimer’s disease.